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1. INTRODUCTION 
1.1. Glaucoma 
1.1.1. Definition 
Glaucoma was first mentioned in ancient Greece; the word "Glaucosis" in Hippocratic 
writings described a blinding disease. The concept of glaucoma was refined over the years, 
where it has evolved from a disease of eye pressure to a disease of optic nerve neuropathy.  
Currently, glaucoma describes a family of multifactorial optical neuropathies characterized by 
a progressive loss of retinal ganglion cells (RGCs) leading to typical optic nerve head (ONH) 
damage and distinctive visual field (VF) defects (1). It can permanently damage vision in the 
affected eye and lead to blindness if left untreated. Glaucoma may present with a variety of 
signs and symptoms, depending upon type and severity, such as: excavation of the optic disk, 
hardness of the eyeball, corneal anaesthesia, reduced visual acuity, seeing of coloured halos 
around lights, disturbed dark adaptation, VF defects and headaches (2). 
 
1.1.2. Classification and prevalence 
Glaucoma is classified by different authors according to cause, the age of onset, initial 
pathological event or mechanism. Glaucoma may be congenital or acquired. According to the 
mechanism by which aqueous outflow is impaired with respect to the anterior chamber angle 
configuration, glaucoma is classified as open-angle or angle-closure glaucoma. It can also be 
classified as primary glaucoma or secondary glaucoma, depending on the presence or absence 
of ocular or systemic disorders that may contribute to pressure rise (3). 
Classification of primary glaucoma is depicted in Table 1, whereas classification of secondary 
glaucoma is depicted in Table 2. 
 
Table 1. Classification of primary glaucoma (3). 
Open Angle Glaucoma (OAG) Angle Closure Glaucoma (ACG) Congenital Glaucoma  
Primary Open Angle Glaucoma (POAG) Primary Angle Closure Suspect True Congenital 
Normal Tension Glaucoma (NTG) Primary Angle Closure Infantile Glaucoma 
High Tension Glaucoma (HTG) Primary Angle Closure Glaucoma Juvenile Glaucoma 
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Table 2. Classification of secondary glaucoma (3). 
 Site of aqueous outflow obstruction Conditions that contribute to rise IOP 
O 
A 
G 
Pre-trabecular Membrane overgrowth: fibrovascular, endothelial or 
epithelial proliferation. 
Trabecular Obstruction: meshwork structure alteration, red cell, 
ghost cell, phacolytic, hypertensive, uveitic, 
pseudoexfoliation or pigment dispersion. 
Post-trabecular Impair of aqueous outflow: occlusion of the Schlem's 
canal, elevated episcleral venous pressure. 
A 
C 
G 
Pupil  block Pupil seclusion, lens subluxation, anterior chamber 
lens implant without iridotomy, adhesive capsular 
block, aphakic pupil block, or phacomorphic. 
Without pupil block Capsular block syndrome without adhesions, iris, 
ciliary body or posterior segment cyst/tumour, 
contract of retrolenticular fibrovascular tissue, 
ciliochoroidal effusion, malignant or late 
neovascularization. 
OAG = Open Angle Glaucoma; ACG = Angle Closed Glaucoma; IOP = Intraocular Pressure. 
 
Glaucoma is the leading cause of irreversible blindness worldwide (4-8), with OAG being the 
most common form (5, 6). It is the second most common cause of blindness after cataracts (4, 
6-7). It was estimated that by year 2010, 45 million people around the world will suffer from 
OAG and 16 million from ACG. This number will be increased to 79.6 million by 2020, and 
of these, 74% will have OAG. The total number with OAG in 2020 will be 58.6 million, with 
the highest number among people of European descent. Bilateral blindness will be raised to 
5.9 million people in 2020 (6).  
Several large population-based studies have been carried out to determine the prevalence of 
glaucoma. Studies in developed countries suggest that more than 50% of the prevalent OAG 
is undetected (8), and this estimate is likely to be higher in developing countries (5).  
In a recent meta-analysis of POAG prevalence that included 46 studies conducted in different 
countries, authors concluded that prevalence increases more rapidly in Caucasian than in 
black and Asian populations, but at all ages black populations have the highest prevalence 
estimates. Data from this study suggests that OAG prevalence in men is approximately 1.4 
times that in women (9). 
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1.1.3. Primary open angle glaucoma (POAG) 
Over the years, there has been a lack of consistent definition of POAG. Since 1980s, different 
definitions and descriptions have been published, based on optic disc, specific VF and 
intraocular pressure (IOP) criteria (10).  
American Academy of Ophthalmology (AAO) defines POAG as a progressive, chronic optic 
neuropathy in adults where IOP and other unknown factors contribute to damage and in 
which, in the absence of other identifiable causes, there is a characteristic acquired atrophy of 
the optic nerve and loss of RGCs and their axons. This condition is associated with an anterior 
chamber angle that is open by gonioscopic appearance (11).  
Today, IOP is not the key part of the definition for POAG. Diagnosis is based on the presence 
of the optic nerve damage, manifested either by optic disc or VF abnormalities (12). Indeed, 
the European Glaucoma Society (EGS) definition of POAG has been arbitrarily subdivided 
into High Tension (HTG) and Normal Tension (NTG) disease according to IOP levels, even 
though they may represent a spectrum of optic neuropathies variably sensitive to IOP (13). 
 
1.1.3.1. Primary open angle glaucoma/ High tension glaucoma (HTG) 
Although HTG and NTG may represent two distinct clinical entities, there is an amount of 
conflicting literature. Studies have identified similarities and differences regarding the 
appearance of the ONH and VF that raised questions about different mechanisms and 
aetiologies of optic nerve damage, making it difficult to draw any clear conclusions (14-16).  
In general, HTG is characterized by elevated IOP without treatment. It is generally bilateral 
but not always symmetrical and presents typically from 35 years of age onward. Clinically, it 
is characterised by an excavation of the optic nerve, referred to as glaucomatous optic 
neuropathy (GON) and a glaucomatous visual field defect (GVFD). Anterior chamber angles 
are open and normal. 
 
1.1.3.2. Primary open angle glaucoma/ Normal tension glaucoma (NTG) 
Historically, NTG was referred to as "low tension glaucoma". Recently, it has been shown 
that OAG is a disease in which the aetiology extends from being predominantly IOP 
dependent at one end (pure HTG), to predominantly IOP independent at the other end (pure 
NTG). Involvement of vascular factors in OAG increases as the predominance of IOP 
decreases (17). Today, it is generally thought that physiological variation of Central Corneal 
Thickness (CCT) is important only for the IOP measurement but not related to any particular 
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type of glaucoma. So, related to NTG, it could be that IOP is falsely lower as an error of 
measurement – that it is actually HTG, but with a thin cornea.  
Two studies showed that the risk of glaucoma increases by 40% and 30% for every 40 
micrometers thinner cornea (18, 19). Except VF defects, that in NTG typically appear deeper, 
steeper and closer to the fixation and GON, there are characteristic disc haemorrhages.  
 
1.1.4. Primary open angle glaucoma suspect  
The term POAG suspect is used to define individuals where not all the criteria that define 
POAG are presented. It refers to an individual with clinical findings or risk factors that 
indicate an increased likelihood of developing POAG.  
POAG suspects may have one of the clinical findings in at least one eye with open anterior 
chamber: appearance of the ONH or retinal nerve fibre layer (RNFL) that is suspicious for 
glaucomatous damage; a VF suspicious for glaucomatous damage in the absence of clinical 
signs of other optic neuropathies; or consistently elevated IOP associated with normal 
appearance of the ONH and RNFL and with normal VF test results. The definition excludes 
known secondary causes for OAG (13, 20). An overlap exists between findings in people with 
early POAG and in those who are glaucoma suspect and without the disease. 
The diagnosis of POAG is usually supported if two or more of the findings are present. 
 
1.1.5. Ocular hypertension (OHT) 
The word "preglaucoma" was used to define individuals with an elevated IOP and without 
detectable glaucomatous damage in the standard clinical eye and VF examination, although 
the majority of them never developed POAG. Diagnosis between ocular hypertension (OHT) 
and early POAG is often difficult (21).  
In a review published in 1998, authors found that 20% of the papers published in the last 15 
years used raised IOP as the only criteria to diagnose glaucoma (22). Today, the OHT term is 
widely used for research and classification purposes for individuals with IOP higher than 21 
mmHg but without any VF, ONH and RNFL changes.  
EGS in its classification states that the term OHT should be only used to indicate that the IOP 
is consistently outside two or three standard deviations from the normal mean, with all other 
ocular findings within normal limits. 
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1.2. Risk factors and pathophysiology 
The exact cause and pathophysiology of the POAG remains unknown and still relatively 
poorly understood despite numerous research in this area. Furthermore, for many years 
authors have suggested that HTG and NTG represent clinical entities with different 
pathogenesis and risk factor implications.   
According to data from newer studies, NTG and HTG represent a continuum disease in which 
elevated IOP is the predominant risk factor, while additional independent factors take 
increasing importance in NTG (13, 14, 17, 23). This definition links different risk factors into 
the pathogenesis of POAG, although there are a number of studies that do not support this 
theory (16, 24). 
 
1.2.1. Risk factors 
In epidemiology, a risk factor is a variable that represents an inherited characteristic, 
environmental exposure, or an aspect of personal behaviour that influences the probability of 
an individual to develop the disease. Risk factors can be divided into various categories. The 
distinction between causal and associated risk factors but also modifiable and non-modifiable 
risk factors is important to understand the pathogenesis, the diagnosing process and to plan 
the management of the disease (25).  
The identification of risk factors has a preventive and therapeutic implication in POAG. The 
most studied risk factor that influences POAG is elevated IOP. IOP is causal and changeable, 
and is the main clinically treatable risk factor that can help prevent POAG (25, 26). Multiple 
theories exist about the role of IOP in the pathogenesis of GON, whereas causal role is 
demonstrated by a number of experimental, clinical and epidemiological studies. 
In humans, IOP has a non-Gaussian distribution with a mean of 16 mmHg and two standard 
deviations on either side that gives a range of normal IOP from 11-21mmHg. In elderly 
people, the deviation is greater than in younger individuals, particularly in women, that may 
range up to 24 mmHg (3, 19, 27). In general, it is noticed that, the higher the IOP, the greater 
the likelihood of glaucoma, although, many eyes with IOP above the average range do not 
develop glaucoma and others within normal range of IOP develop it.  
In addition to the level of IOP, it seems that of relevance is also circadian and day to day IOP 
fluctuation (27, 28). 
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Some POAG risk factors are not changeable, however, they are studied because of their 
importance in identification of individuals that are indicated for close ophthalmic supervision.  
General risk factors that may contribute to POAG are summarized in Table 3, whereas ocular 
and systemic risk factors are summarized in Table 4.  
Several ocular, systemic and general risk factors have been proposed to play a role in the 
POAG pathogenesis and conversion of OHT to POAG but the most studied and with the 
growing body of evidence are: age, race, ethnicity, family history, genetics, vascular factors, 
diabetes mellitus, myopia, corneal thickness, and ONH. Some books also mention lifestyle, 
socioeconomic status, alcohol consumption or smoking as possible risk factors. 
 
Table 3. General risk factors that may contribute in POAG  
General 
risk factors 
Description References 
 
 
AGE 
Age appears to be an important risk factor. Prevalence studies demonstrate 
that it is unusual to see the disease before the age of 40, and more than three 
times higher after the age of 65. It is believed that damage progresses faster 
in older people. 
3, 21, 
25, 28 
 
 
RACE 
It is not clear whether race is directly affiliated as a risk factor, or if there are 
other associated factors that increase the prevalence in a certain race. 
Prevalence studies state that POAG prevalence in black people is higher, 
develops earlier and is more severe while NTG occurs more in Japan. 
3, 11, 
21, 29 
 
 
FAMILY 
HISTORY 
The exact risk of family history cannot be estimated, the disease develops in 
older individuals and long term follow-up is required. Responsible genes can 
show incomplete penetrance and variable expressivity in some families. 
IOP, facility of aqueous outflow and optic disc size are also genetically 
determined. First-degree relatives of patients with POAG are at an increased 
risk. 
3, 11, 
21, 29 
 
GENETICS 
Genetic studies detected different mutation in loci of the human genome 
associated with POAG like: MYOC, OPTN, WDR36, OPA1 and the NTF4 
gene. 3, 11, 25 
 
GENDER 
Gender is not listed in the risk factors in the majority of glaucoma books. 
Studies did not find a clear-cut evidence of gender as a risk factor, although 
some studies have found a higher prevalence of NTG in females. 3, 25 
POAG = Primary Open Angle Glaucoma; NTG = Normal Tension Glaucoma; IOP = Intraocular Pressure; MYOC = 
Myocilin; OPTN = Optineurin; NTF4 = Neurotrophin; 4; WDR36 = WD Repeat Domain 36; OPA1= Optic Atrophy 1. 
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Table 4. Ocular and systemic risk factors that may contribute in POAG  
Ocular 
risk factors 
Description References 
 
 
ONH 
ONH characteristics are now part of the definition of POAG, and in many 
protocols are not listed in risk factors. For many years enlarged ONH was 
considered as a risk factor. Recently, cup/disc ratio, cup/disc ratio 
asymmetry and pattern standard deviation are described in literature as 
additional risk factors. 28, 30 
 
 
CCT 
CCT is lower in NTG patients and higher in people with OHT. This 
relationship led to the idea that CCT may also be an independent risk factor. 
Indeed CCT, curvature of the cornea, cornea biomechanics can all affect the 
measurement of IOP. There is also an opposing thought on whether CCT 
contributes to the conversion of OHT in POAG. 
11, 19, 
28, 30 
 
 
 
 
MYOPIA 
Supporting evidence is not strong but, it is thought that myopic eyes maybe 
at increased risk for POAG. This relationship remains controversial. People 
with myopia are more likely to seek eye care and thus have a higher 
probability of having glaucoma detected early, disc evaluation is 
complicated, retinal changes and high refractive errors can cause visual 
field abnormalities. 
11, 21, 
25, 29 
Systemic 
risk factors 
  
 
 
VASCULAR 
DISEASES 
Relationship between POAG and vascular diseases is difficult to prove and 
still remains controversial. The higher probability of involvement of 
vascular factors is when POAG occurs or progresses at lower IOPs. A range 
of vascular diseases is thought to be associated with the development and 
progression of some POAG cases like: systemic hypertension, systemic 
hypotension cardiovascular diseases, migraine, and vasospasms. 
21, 28, 31 
 
 
DIABETES 
MELLITUS 
Linkage between POAG and diabetes mellitus (DM) has been proposed due 
to vascular deregulation in diabetes. There are some studies that show a 
correlation between diabetes mellitus and POAG, but it still remains 
controversial if diabetes is an independent risk factor. 3, 21 
ONH = Optic Nerve Heat; OHT=Ocular Hypertension; CCT = Central Corneal Thickness; IOP = Intraocular pressure; 
POAG = Primary Open Angle Glaucoma; NTG = Normal Tension Glaucoma. 
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1.2.2. Pathophysiology 
A definitive description of processes that causes the characteristic atrophy of the optic nerve 
and loss of RGCs and their axons in POAG still needs to be established.  
RGC death in POAG occurs predominantly through apoptosis rather than necrosis, where the 
pre terminal event is calcium ion influx into the cell body and increase of intracellular nitric 
oxide (3). An excessive release of the excitatory neurotransmitters in the extracellular 
environment after the axon death may trigger the death of the neighbouring neuron cells (26). 
It is demonstrated that after initial injury, progressive pathological changes result also with 
changes in RGC bodies, photoreceptors, lateral geniculate nuclei, visual cortex and lamina 
cribrosa (32-36).  
On a histological level, it is characterized by loss of axons, blood vessels and glial cells that 
seem to start at the level of lamina cribrosa (21). These alternations cause tissue remodelling, 
leading to the enlargement or the asymmetrical deep of the optic cup, optic disc haemorrhage, 
peripapillary atrophy, neuroretinal rim (NRR) and RNFL thinning that is unique for GON 
(37, 38). 
Several theories describe the occurrence of optic neuropathy in POAG, but most widely 
studied are the mechanical and vascular theory. However, it is generally recognized that 
POAG can be caused by a mixture of both mechanisms (39, 40). These mechanisms may 
include axoplasmic flow reduction, interference in the delivery of nutrients or removal of 
metabolic products, neuronal growth factors deprivation, oxidative stress and the initiation of 
immune-mediated damage.  
The precise mechanism is still a hot topic on glaucoma research, and the theories will be 
discussed only because of their historical importance.  
 
1.2.2.1. Mechanical theory 
The mechanical theory of POAG is based on the mechanical force that causes elevated IOP in 
lamina cribrosa, glia and axons of ONH (41).  
Elevated IOP is caused due to the altered rate between aqueous secretion and outflow 
resistance in the presence of open anterior chamber angle. The increase of outflow resistance 
is supposed to be caused by structural alternation of trabecular meshwork. There is a 
histopathological and biochemical evidence of several factors contributing to these 
mechanisms, however they are not well understood (29).   
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In the context of mechanical theory of POAG, it is believed that pressure gradient is more 
important around the ONH rather than the absolute IOP (3). According to this theory, direct 
compression of axons and the deformation of the pores and channels of the lamina cribrosa 
disrupts axoplasmic flow and leads to RGCs death (26).  
Most studies support the theory that the level and duration of increased IOP is important for 
the development of POAG, however, some authors state that factors such as scleral rigidity 
(42) are of primary interest. 
Furthermore, affection of ONH in NTG beside the normal IOP level, and absence of 
glaucomatous damage in OHT despite the elevated IOP leads to idea that in individuals 
alternative or additional causative factors contribute to the development of GON. 
 
1.2.2.2. Vascular theory 
The vascular theory of POAG is based on the instability of blood flow in the microvasculature 
that supplies ONH (43, 44).  
Blood flow instability contributes to GON development through ischemic and hypoxic insult 
of the ONH tissues, including: the RGC axons, astrocytes, glial cells, pericytes and the central 
retinal vessels (43).  
Possible mechanisms that cause GON may extend from: losing of capillaries, reductions in 
blood flow, failure of vascular regulation, interference with delivery of nutrients or removal 
of metabolic products from axons, and increases in vessel rigidity at both levels (3, 28). 
Evidence of decreased blood flow in OHN is demonstrated by histopathology, fundus      
fluorescein angiography, and Doppler measurements (45-47). Some studies demonstrated 
impairment of normal autoregulation of retinal vessels or atrophy of peripapillary capillaries 
that supply the RNFL in POAG patients (46-48). 
A lot of research has been conducted to explore the role of ocular and systemic vascular 
factors in the pathophysiology of POAG, but still they are not well understood and remain 
controversial.  
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1. 3. Diagnosis and prognosis  
For the proper management of POAG, comprehensive evaluation of the eye is important. It 
can reveal the diagnosis, severity and the progression of the disease. All components of the 
eye evaluation should be performed and more than one visit is required (11, 49). 
POAG identification may require a variety of modalities for the clinical examination, but 
some are particularly important. Examination includes: anamnesis; refraction evaluation; 
pupil, and slit-lamp examination of the anterior segment; tonometry; pachymetry; 
gonioscopy; fundus, ONH and RNFL evaluation; VF assessment and electrophysiology. 
 
1.3.1. Anamnesis 
POAG has a painless and insidious nature, and patients usually do not report symptoms 
during the early phase (26). Very rarely, patients with elevated IOP will note brow arch and 
haloes around lights. Visual acuity alternation occurs only in advanced disease or when 
scotoma is close to fixation, and VF defects are not consciously perceived by patients (2, 28, 
29). In a recent study of moderate glaucoma patients with a range of GVFD, it was found that 
VF filed is not perceived as a black tunnel or as black patches masking the field (50). Some 
patients may suffer from loss of chromatic or achromatic sensitivity, reduced contrast 
sensitivity and increased blur.  
Since POAG patients lack symptoms, the initial examination history should contain: ocular 
history, family history, and systemic risk factors that can be associated with POAG.  
An assessment of the impact of patient’s visual function in relation to hobbies, employment, 
and daily living should be performed (27). 
 
1.3.2. Clinical examination 
Evaluation of refraction to obtain the best corrected visual acuity (BCVA) is crucial for 
accurate VF testing, but also to exclude clinical confusion of disc morphologies that can be 
due to early myopia (21).  
Pupils should be examined for reactivity and afferent pupil defect that may be present in eyes 
with advanced optic nerve damage in highly asymmetric cases of glaucoma (51). 
Examination of the anterior segment in slit-lamp is done to exclude other forms of glaucoma 
or ocular pathologies. In POAG the anterior segment is without any pathology. 
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1.3.3. Tonometry 
Diagnosis of POAG cannot be made according to the IOP level; however tonometry is always 
performed before gonioscopy and pupil dilatation. Beside diagnosis, tonometry is used to 
evaluate the effect of glaucoma treatment on the IOP.  
IOP can fluctuate by the influence of numerous factors like: time of day, heartbeat, 
respiration, exercise, fluid intake, topical and systemic medications. In POAG patients, IOP 
fluctuates well beyond that is seen in normal populations and tonometry measurements should 
be recorded at different hours of the day or on different days (3, 11, 21). This way of 
measurement is important to: establish the diagnosis of NTG, stop the progression of POAG 
due to unrecognized fluctuations, and evaluate the ability of anti-glaucoma therapies to lower 
the IOP throughout the 24h day (52-54).  
A number of tonometers utilizing different techniques have been produced. Goldman 
applanation tonometer remains the preferred one and relatively accurate, whereas  
non-contact tonometers used more for screening purposes are less precise. Accuracy of any 
types of tonometers can be affected by different factors, the most important are CCT and   
corneal biomechanical properties (corneal hysteresis and corneal resistance factor) (25).  
 
1.3.4. Pachymetry 
Measurement of CCT is recommended as it influences Goldman aplanation tonometry (GAT) 
readings. However, there is no agreement as to whether there is a validated correction 
algorithm for GAT and CCT (25, 55). Normal CCT is 540+/-30μm, whereas each glaucoma 
cabinet has tables for correction of IOP in respect to pachymetry findings.    
It remains unclear whether CCT represents a risk factor due to its effect on IOP measurement 
or whether CCT is a risk factor itself.  
 
1.3.5. Corneal hysteresis 
Corneal hysteresis (CH) measurement reflects the viscoelastic properties of the cornea and 
gives an indication of its biomechanical integrity. 
CH does not show any significant variations throughout the day (25), and has greater impact 
than CCT and corneal curvature in the IOP measurement errors (56).  
Low CH value is a risk factor for underestimation of the IOP and a high CH value for 
overestimation, however, CCT and CH are independently associated with IOP (57). 
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1.3.6. Gonioscopy 
POAG diagnosis requires careful evaluation of the anterior chamber angle to exclude 
secondary causes of IOP elevation. Indirect and direct gonioscopy techniques are used for this 
examination and a number of lens constructed based on these techniques. 
In the office, most applicable is indirect gonioscopy (58). Beyond gonioscopy, that is a 
subjective technique, available imaging techniques for evaluation of the anterior chamber 
angle are: ultrasound biomicroscopy (UBM) and anterior segment optical coherence 
tomography (OCT). These two techniques are non-invasive, but do not replace the 
goniosocpy and are used just as complements (25, 27). 
 
1.3.7. Optic nerve head and retinal nerve fibre layer examination 
In POAG diagnosis and management the most critical part is evaluation of ONH and RNFL. 
Alternations in ONH and RNFL are the most typical for POAG, and often occur before VF 
defects (26, 29, 59). It is important to notice: NRR thickness, disc asymmetry, pallor of the 
disc, disc haemorrhages, peripapillary atrophy, blood vessel changes, visibility and loss of 
RNFL (21). Relevant variables that can be extracted are: horizontal and vertical cup-to-disc 
ratio, volume of cup and rim, and average RNFL thickness. Data of these parameters should 
be collected in drawings or visualisation techniques, and quantitative measurements by 
instruments should be performed. 
Evaluation techniques for these structures involve: subjective techniques (direct and indirect 
ophthalmoscopy), stereoscopic fundus photography and imaging techniques. Currently, the 
most common used imaging techniques are: scanning laser polarimetry (SLP), confocal 
scanning laser tomography (CSLT), time domain and spectral domain OCT.  
 
1.3.8. Visual Field Function 
Except ONH and RNFL evaluation, VF test is crucial for POAG diagnosing and management. 
This psychophysical test remains the primary visual function test performed in POAG. It 
reflects characteristic changes of the RNFL anatomy and determines the impact of VF on a 
patient’s quality of life and activities of daily living (60, 61). Interpretation of VF test should 
be very careful as the results can be affected by: ability of patient and examiner, fixation, 
luminance, stimulus, refraction, pupil size and opacities of eye media (3).  
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In POAG, defects in VF occur at 30°, models include: paracentral and arcuate or Bjerrum's 
scotoma, nasal step, altitudinal or temporal wedge defects and less characteristic changes like 
general depression. In early stages of the disease defects are located in the periphery of the 
visual field (3, 21, 27, 29). Different devices that use different techniques and programs have 
been constructed for VF testing. Some are better for identification and others for following 
the progression, however, all of them have weaknesses. Currently, most preferable for 
assessment is the automated static perimtery. Suprathreshold static perimetry is suited for 
rapid screening, while manual perimetry remains helpful in documenting defects outside the 
central 30° and in monitoring end-stage VF loss (11, 29). Sensitive assessment of POAG 
progression can be performed by independent programs that calculate and compare VFs (62).  
 
1.3.9. Electrophysiology 
Electrophysiological examination techniques provide localised information of RGCs 
functions (63, 64). In POAG, RCGs are lost before the appearance of subjective VF defects 
(65), however, electroretinography (ERG) and visually evoked potential (VEP) examinations 
are not routinely performed. They are a part of the objective testing when patients are not able 
to perform perimetry. 
 
1.3.10. Genetic Testing 
Association of the genes with POAG does not have the specificity required for a gene-based 
diagnostic or screening test, although they may be helpful to screen individuals in risk and to 
decide for therapy. These tests can be carried out only in some specialised laboratories and are 
not performed routinely (25). 
 
1.3.11. Ocular Blood Flow Measurement 
Measurement of ocular blood flow (OBF) in POAG diagnosis is based on the possible 
influence of vascular risk factors of the disease, but this assessment is not supported by 
evidence. Furthermore, information is practically useless for clinicians. Only few guidelines 
recommend treatment of POAG patients in regard to reduced OBF (25, 66). Different 
techniques and instruments are available, but the ideal test to measure comprehensive OBF of 
patients is yet to be developed.  
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1.4. Treatment  
The aim of therapy in POAG is to prevent functional impairment of vision by slowing the 
apoptosis of RGCs within a patient's lifetime. Elevated IOP, which is the main factor 
implicated in mechanisms that are thought to precipitate RCGs apoptosis in POAG, is 
currently the only treatable factor approved by many guidelines (11,13). 
Many studies demonstrate that decreasing IOP prevents both conversion of OHT to POAG 
and progression of POAG (67-69), however, it remains unclear which modality of the IOP-
lowering therapy is the most effective, with the fewest adverse effects and lowest cost.  
Non-IOP lowering therapy toward factors that may play a role in POAG pathogenesis are 
being investigated (70-72), but until now neither proved enough evidence. 
 
1.4.1. Conservative therapy 
Medical therapy has an important role in POAG treatment, especially during the last years 
that the pharmaceutical market has presented a variety of IOP lowering drugs and different 
combinations. Drugs are considered as the first line of treatment, and in most patients they 
can control the disease alone.  
Medications reduce elevated IOP either by reducing aqueous production or by increasing 
aqueous outflow through the conventional or the unconventional pathway (73, 74). Table 5 
summarizes five major classes of IOP-lowering drugs: direct and indirect acetylcholine 
receptor agonists (cholinomimetics); alpha-adrenoceptor agonists (α-agonists); carbonic 
anhydrase inhibitors (CAIs); beta-adrenoceptor antagonists (β-blockers); and prostaglandin 
analogues (PGAs) (75, 76). Each group comprises of several individual drugs, whereas fixed 
combinations are also available. Some drugs are not used anymore as the new drugs from the 
same group, which have greater effect and less adverse effects became available. 
 
1.4.2. Laser and surgical therapy 
Indications for laser and surgical therapy changed with the introduction of new generations of 
lasers and novel surgery devices with low morbidity for surgical intervention but, still remain 
the second line of treatment. 
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Table 5. Five major classes of IOP-lowering drugs  
α-agonists β-blockers CAIs PGAs Cholinomimetics 
Dipivefrin Timolol Acetazolamide Travaprost Pilocarpine 
Brimonidine Levobunolol Methazolamide Latanaprost Carbachol 
Apraclonidine Betaxolol Dorzolamide Brimatoprost Physostigmine 
Epinephrine Carteolol Brinzolamide Tafluprost Echothiopate 
Clonidine Metipranolol Diclorphenamide Unoprostone Demecarium 
 Pindolol   Aceclidine 
 Befunolol   Achetylcoline 
α-agonists = Alpha-Adrenoreceptor Agonists; β-blockers = Beta-Adrenoreceptor Antagonists;  
CAIs = Carbonic Anhydrase Inhibitors; PGAs = Prostaglandin Analogues;  
Cholinomimetics = Direct and Indirect Acetylcholine Receptor Agonists. 
 
Lasers can be considered as a first line therapy in some patients, usually adjunct to medical 
therapy or with attempt to gradually withdraw medical therapy, although the reduction of 
medication is a secondary consideration (3, 21). Laser procedures used to lower IOP include: 
trabeculoplasty, iridotomy, iridoplasty and cycloablation.  
Laser trabeculoplasty is a procedure most commonly used in case of POAG. It lowers IOP by 
targeting trabecular meshwork by argon, diode and selective laser or alternative lasers like 
continuous wave length lasers of red and infrared wavelengths (28).  
 
In POAG patients, surgery is considered when maximal drug therapy is not effective, 
although it can reduce the number of patient visits to the doctor and can achieve a lower IOP 
without additional medications.  
Commonly performed surgery is a partial thickness procedure called guarded trabeculectomy. 
Different modifications of trabeculectomy evolved to prevent failure of filtration with the use 
of anti-metabolites agents and aqueous shunts (13, 21). Several newer non penetrating 
surgeries with lower morbidity have been presented recently, however these options are not 
much studied (27, 77). Combined surgeries of glaucoma and cataracts are also performed 
lately as prevalence of glaucoma and cataracts in the eye increases with age (25, 78). 
 
Special skills and expensive instruments are required to perform laser and surgical 
procedures, and therefore they are not in the aim of this thesis. 
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1.5. Public health consequences  
In POAG the optical nerve destruction is usually slow, however, visual loss cannot be 
reversed. VF loss normally starts by affecting the peripheral vision, therefore remains 
unrecognized for a long time. Late detection with a consequent delayed treatment 
commencement is a major risk factor for blindness. 
The incidence of blindness from POAG has been variously reported. It was estimated that  
20 years into the diagnosis and treatment of POAG, incidence of blindness was 27% 
unilateral and 9% bilateral, with 15 patients legally blind at least in one eye at the time of 
diagnosis (79). Many issues related to blindness from POAG are linked to poverty and 
incidence maybe higher in developing countries where the diagnosis and treatment are 
delayed. However, if diagnosed and treated in time, most POAG patients will retain useful 
vision for their entire lives. This is especially problematic in developing countries with 
limited public health resources for diagnosis, treatment and reimbursement of POAG patients. 
The International Classification of Diseases (ICD), the standard diagnostic tool for 
epidemiology, health management and clinical purposes of the World Health Organization 
(WHO) defines blindness as visual acuity of less than 20/400 (6/120) or VF loss to less than 
10° in the better eye with the BCVA. By this tool low vision is defined as visual acuity equal 
to 20/200 (6/60) or VF loss to less than 20° in the better eye with the BCVA (80). WHO 
Member States use this tool for national mortality and morbidity statistics, but also for 
reimbursement and resource allocation decision.  
While in many parts of the world sophistication and efficacy of diagnostic and therapeutic 
methods rely on expensive equipment and drugs, and research is focused in etiological issues, 
in developing countries the primary goal is adequate preventive and therapeutic care related to 
their limited budget (81). First step to achieve this is identifying people with a higher risk of 
developing POAG, and to approve a public health strategy of treatment with the lowest-cost 
intervention.  
Although the economic evaluation for POAG is in its infancy, practical adaptation of data 
analysis of risk factors and treatment modalities is highly important for these countries, 
because physicians and regulations often adopt non cost-effective strategies enhancing the 
perception of findings (81, 82). 
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1.6. The problem 
As illustrated already by its classification, glaucoma in general is a very complex and 
multifaceted condition. The current understanding is that the two major classes – open angle 
(OAG) and angle closed (ACG) glaucoma – are actually different diseases with different 
pathophysiology and different risk/causative factors. OAG is by far more prevalent (75% of 
all glaucoma cases) and its primary form, i.e., primary open angle glaucoma, POAG, bears the 
major part of the overall healthcare burden of glaucoma.  
 
Although not without controversy, the definition, features and clinical characteristics of 
POAG are nowadays well defined, but the primary cause(s) that triggers the cascade of events 
resulting in POAG is less clear and is in the focus of the current research.  
Elevated IOP is the only clearly defined major risk factor for development of POAG, 
although this relationship is not a “perfect” one. There is also a growing body of evidence 
suggesting that other factors may play a role in pathogenesis of POAG, but the contribution of 
these multiple factors is uncertain and different etiological theories on POAG have been 
proposed. In the attempts to improve the public health strategies for coping with the overall 
burden of the disease, systematic evaluation of the existing evidence on potential relevant 
other (apart from IOP) risk factors is warranted. 
 
Reduction of IOP prevents both conversion of OHT to POAG and progression of POAG, i.e., 
progression the optic neuropathy and impairment of vision. Different treatment modalities 
targeting factor that may play a role in POAG pathogenesis are being investigated, but for the 
time-being the only modality recommended by the professional guidelines is IOP-lowering 
treatment (11, 13, 8). Reduction of IOP can be achieved by medications, laser and surgical 
therapy. Topical drug therapy is a standard initial treatment, whereas the latter two options are 
implemented mainly when conservative therapy is not effective, not tolerated or not utilized 
by the patient. According to the guidelines, IOP-lowering treatment should start with a mono-
compound therapy and should aim to reduce IOP by 20-30%. A rational first line mono-
compound drug is the one installed as infrequently as possible for the therapeutic effect and 
with the fewest side-effects. If the first line medication is not effective or not tolerated it could 
be substituted, another drug may be added (unfixed combination) or a patient could be 
switched to a fixed combination of different compounds (9, 11, 13).  
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A recent comprehensive evaluation (83, 84) demonstrated a high level of evidence of efficacy 
in IOP reduction of various topical pharmacological treatments but with some uncertainty 
regarding their mutual relationship in this respect. The latter was in part due to inconsistent 
results of some studies and to the complexity of the setting (e.g., different forms of OAG, 
treatment-naïve/previously unsuccessfully treated patients) and treatment modalities (mono-
compounds, fixed/unfixed combinations) (83, 84). It is therefore of interest to evaluate the 
existing evidence on relative efficacy, tolerability and cost-effectiveness profile of mono-
compound topical medications specifically in POAG and OHT, the most common conditions 
requiring IOP-reducing therapy. 
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2. HYPOTHESIS AND AIMS OF THE STUDY  
The present study was motivated by three hypotheses related to POAG/OHT:  
I. There might be other, apart from increased IOP, factors with relevant individual 
contributions to the risk of POAG. 
 
II. There might be practically relevant differences between IOP-lowering treatments 
regarding efficacy and safety in POAG/OHT. 
 
III. There might be relevant differences between IOP-lowering treatments regarding cost-
effectiveness profile in POAG/OHT. 
 
By the year 2010, there were already 112 systematic reviews/meta-analyses in the field of 
glaucoma (85, 86) embracing a variable number of primary studies addressing different 
aspects of the disease. Considering the continuous research interest in these topics, it is 
reasonable to assume that the body of data has further increased over the past few years.  
Under such circumstances, a systematic synthesis of the existing research appears to be an 
appropriate methodological approach to achieve the aim of improved overall management 
(preventive and curative) of glaucoma, more specifically, of POAG and OHT.  
 
In this respect, the present study aims to answer specific research questions: 
1. What is the existing evidence on factors other than the increased IOP that are potentially 
modifiable or could be used for timely identification of people at an increased risk of 
POAG? 
 
2. What is the existing evidence on relative efficacy and safety of mono-compound topical 
IOP-lowering medications in treatment of POAG/OHT? 
 
3. What is the existing evidence on relative cost-effectiveness of the mono-compound 
topical IOP-lowering medications in treatment of POAG/OHT? 
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3. MATERIALS AND METHODS 
In the context of evidence-based medicine, systematic reviews/meta-analyses are generally 
considered to provide the highest level of evidence based on filtered data. Considering the 
reports indicating existence of a large number of such studies related to glaucoma (85, 86), 
the present study was conceived as an overview of systematic reviews: a method of 
identification, qualitative and quantitative evaluation and synthesis of the available clinical 
evidence about the posed research questions. Primary studies were considered only in case of 
out-dated or incomplete (missed studies, non-evaluated endpoints) systemtic reviews. 
Although related to the same topic, the questions conceptually differed: one addressed 
“prognostic relationships” and was to be based on evaluation of observational data 
(systematic reviews/meta-analyses of observational studies); the other addressed “therapeutic 
relationships” and was to be based on interventional studies (systematic reviews/meta-
analyses of interventions).  
Since the nature and methodology of the observational and interventional primary studies 
differ, the methodological characteristics of systematic reviews of such studies also differ. 
Consequently, an overview of reviews has certain methodological features that depend on 
whether it deals with prognostic or therapeutic issues. However, most of the methodological 
steps are common to all overviews of reviews. The present study followed the format and 
methods for an overview of systematic reviews as proposed by the current Cochrane 
Handbook for Systematic Reviews (version 5.1.0., 2011) (87).  
This section first depicts the common methodological characteristics of both parts 
(“prognostic” and “therapeutic”) of the present study, followed by methodological particulars 
for the each part. The common elements are: literature search; selection of studies; data 
collection; assessment of study quality; data synthesis and evaluation of quality of evidence. 
 
3.1. Literature search 
All performed literature searches included searches of electronic databases of published 
studies, as well as hand searches – reference lists of identified relevant publications. 
Unpublished material was considered to be irrelevant therefore no attempts were made to 
identify. Common search strategies [(separately for prognostic and interventional studies) 
(Tables 8, 9)] were defined by me and mentor and then searches were performed by each one 
individually. Assistance of a professional librarian was used in this step. Direct search terms 
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and control terms were adapted to each database. All searches were conceived to be sensitive 
not specific, hence no restrictions were set in respect to the journal, publication date, 
geographical location or language. Literature searches on both topics were repeated on two 
occasions during 2013, and final searches were concluded by the end of February 2014. 
 
3.2. Selction of studies (reviews) 
The inclusion of studies (reviews) in the present overviews was based on predefined criteria 
formulated in collaboration with mentor (study selection protocols 3.6.2 and 3.7.2). Study 
(review) selection was carried-out independently by me and mentor, but a consensus had to be 
reached at two steps in the selection process. The entire process consisted of the following 
steps:  
a.  identification and removal of duplicate publications from the body of records identified by 
the initial search; 
b.  screening of non-duplicates based on titles and abstracts for potential eligibility for 
inclusion. At this step, the selections made by me and mentor were compared and 
discrepancies were resolved by a consensus; 
c.  retrieval and full text evaluation of the selected studies for final assessment of eligibility 
for inclusion. At this step, the selections were again compared and discrepancies resolved 
through a consensus. 
 
3.3. Data collection 
Data collection forms were defined in a collaboration with mentor in order to collect: 
a.  descriptive data on included reviews (e.g., author name, publication year, the number and 
type of included primary studies [e.g., case-control or cohort observational studies for 
prognostic factors; randomized or non-randomized controlled trials of interventions], number 
of patients, evaluated questions [i.e., risk factors, treatments]); 
b.  data relevant for quality assessment of the included reviews which differed for those 
dealing with observational and those dealing with interventional studies (see below); 
c.  effect measures provided by the reviews (i.e., end results of the pooled analysis of primary 
studies).  
The data collection process was performed independently by me and mentor, extraction forms 
were compared and discrepancies resolved by a consensus. 
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3.4. Assessment of study (review) quality 
Each included review was assessed for quality independently by me and mentor. The final 
results were compared and discrepancies were resolved by a consensus. The process of 
assessment of quality is outlined in Figure 1:   
a.  there are two elements of quality of systematic reviews: (i) reporting quality and (ii) 
“technical quality”. The latter depends on methods used to assess the level of various biases in 
primary studies; methods to protect the systematic review from publication bias; methods 
undertaken at the systematic review level to reduce biases arising from individual studies 
(e.g., sensitivity analyses); and data pooling techniques;  
b.  these elements were assessed using validated tools: recommended check-lists were used to 
evaluate reporting quality and Cochrane Handbook for Systematic Reviews (87) was 
consulted to evaluate methodology. Figure 1 depicts the two check-lists used that are 
described in more detail in subsections 3.6.3 and 3.7.3, on overview of reviews of 
observational studies (MOOSE) (88) and on overview of reviews of interventional studies 
(PRISMA)(89);  
c.  finally, a quality grade was assigned to each included review using the AMSTAR tool (90) 
(Figure 1).  
 
Figure 1. Schematic representation of the assessment of quality of included reviews and 
of definition of the level of quality of the body of evidence.  
MOOSE (88) = Meta-analysis Of Observational Studies in Epidemiology;  
PRISMA (89) = Preferred Reporting Items for Systematic Review and Meta-Analyses; 
AMSTAR (90) = Tool for Assessment of Multiple SysTemAtic Reviews; 
GRADE (91) = Grading of Recommendations Assessment, Development and Evaluation. 
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AMSTAR (Assessment of Multiple SysTemAtic Reviews) is a validated tool (face and 
construct validity, inter-rater agreement) (90, 92) for grading quality of systematic reviews 
(regardless of whether they deal with observational or interventional primary studies). It is 
depicted in Table 6. 
 
Table 6. The AMSTAR tool for grading quality of systematic reviews in healthcare (93). 
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AMSTAR poses 11 questions related to methodological quality of a systematic review and 
offers four possible answers: “Yes”, “No”, “Can’t answer (?)” and “Not applicable”. Only a 
“Yes” assigns a point to a review. The maximum score is 11. There are, however, no defined 
cut-off values of the AMSTAR score that would categorize reviews by quality: simply, 1 is 
the lowest and 11 is the highest level of quality of an individual review (93). 
 
3.5. Data synthesis/Quality of evidence 
In the final step, the present overview(s) evaluated the quality of the total body of evidence 
relevant for the posed research questions. This process was also conducted separately by me 
and mentor and disagreements were resolved through a consensus. 
For this purpose, the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) system of evaluation of quality of evidence was used. The GRADE system (94 -
102) is a complex and comprehensive system of assessing quality of evidence in healthcare 
and is recommended for this purpose by the Cochrane Collaboration. 
The GRADE system can be applied to a single study, e.g., observational (epidemiological) 
study or an interventional trial, or to systematic reviews embracing more such studies. 
As a final result, the GRADE assigns one of the 4 categories of “quality” to the “body of 
evidence” (i.e., one study, more studies, a systematic review or a number of systematic 
reviews – depending on what represents the “body of evidence”), as depicted in Table 7. 
In the case of systematic reviews, i.e., the body of evidence consisting of a systematic review, 
the GRADE quality rating process is broader and goes beyond what is assessed by the 
AMSTAR tool: it does not consider only the methodological quality of the systematic review 
per se, but considers also elements like: (i) total number of included studies; (ii) the number 
of patients per study and overall; (iii) quality of individual studies and the quality of the 
systematic review; (iv) precision of the (pooled) estimates; (v) level of heterogeneity; (vi) 
outcome measures in individual studies and the systematic review and their practical 
relevance; (vii) the data synthesis method, i.e., not only its technical correctness, but also its 
logic, e.g., only direct vs. mixed or indirect comparisons.  
Hence, the level of quality of the body of evidence assessed by the GRADE process subsumes 
the results of AMSTAR, but adds additional elements. 
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Table 7. The GRADE system categorization of “quality of the body of evidence” 
(pertaining to a particular research question) in healthcare. 
Level of quality Marked as Description/definition 
 High 4 pluses () We are very confident that the true effect lies close to that of 
the estimate of the effect. 
 Moderate 3 pluses (F) We are moderately confident in the effect estimate: the true 
effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different. 
 Low 2 pluses (FF) Our confidence in the effect estimate is limited: the true 
effect may be substantially different from the estimate of the 
effect. 
 Very low 1 plus (FFF) We have very little confident in the effect estimate: the true 
effect is likely to be substantially different from the estimate 
of the effect. 
 
To reach the final grade (of quality), the GRADE process evaluates 5 domains: 
Limitations/bias – Depending on what represents a body of evidence (a single study, several 
studies, a systematic review; a randomized controlled trial, an observational study), this 
domain has certain specificities. Assessment requires knowledge about appropriate methods 
for each of the types of studies and recognition of potential methodological limitations and 
inadequate protection from bias – i.e., flaws in design and conduct. For example, in 
interventional studies limitations/biases arise from: non-randomization, inadequate allocation 
concealment, small single-center trials, non-blinding, inadequate subject evaluation methods, 
inadequate (for the aim) patient selection, etc. In observational/epidemiological studies, 
limitations arise from not accounting for confounders, inadequate definition of the sample (of 
the population) etc. In systematic reviews, limitations/biases can be generated at both the 
primary study level and the meta-analytical level. Inadequate statistical analysis is a common 
source of limitation/bias in any type of study. 
Inconsistency – This is a typical item for evaluation in systematic reviews/meta-analyses and 
pertains to high heterogeneity (as detected in formal assessment or as apparent discrepancy in 
the results of individual studies) as a potential obstacle for data pooling. In individual studies 
it may refer to, e.g., inconsistent results in intent-to-treat and per-protocol data sets, or 
inconsistency between primary and secondary endpoints. 
Indirectness – This item pertains to several different characteristics. Evidence (a single study, 
a systematic review) can be only indirectly related to the posed research question if: a) it was 
gathered in population (sample) or system that differs from that to which the research 
question is addressed; b) it was gathered with an intervention that is not exactly the one at 
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which the research question aimed; or if an inadequate comparator is used; c) it assessed 
surrogate outcomes. Indirectness results in poor generalizability of the results. In meta-
analyses, indirectness has one additional potential source – indirect comparison, e.g., in 
network meta-analysis. 
Imprecision – This item pertains to imprecise estimates (e.g., wide confidence intervals) in a 
study (or a systematic review) and is typically due to small samples. 
Publication bias – This item pertains primarily to systematic reviews. 
 
The process of grading starts with an “a priori” grade that could then be either reduced or 
increased. In the case of evidence related to interventions, randomized controlled clinical 
trials (RCTs) and systematic reviews have a “high quality” starting point. Subsequently, each 
of the above 5 domains is assessed and the starting grade is either unchanged (by item), or it 
is reduced by 1 or 2 steps (“downgrading by 1”, i.e., -1; “downgrading by 2”, i.e., -2). 
Downgrading by -1 is implemented when body of evidence is seriously flawed at a certain 
item, and downgrading by -2 is implemented when it is very seriously flawed. 
For observational studies, the starting “a priori” grade is “low quality”, however, it could be 
upgraded in the assessment process based on the following: a) a large effect is detected that is 
likely not biased; b) there is a “dose-dependent” trend (e.g., in epidemiology – more extensive 
exposure results in a greater effect of a risk factor); c) all plausible residual confounding 
(effects not accounted for in data analysis that could have affected the outcome) would (i) 
reduce the demonstrated effect or (ii) would increase the effect, but none is shown. Hence, 
observational studies could also attain “high quality”. Theoretically, RCTs/systematic reviews 
downgraded for some reason could be also upgraded by the presented criteria. 
All systematic reviews included in the presented overviews were assigned the GRADE 
quality of evidence score and those that attained at least the “moderate quality” level were 
then used to derive answers to the posed research questions.  
In case of out-dated or incomplete data, data from high quality primary studies were pooled. 
In this case priority was given to random effects estimates rather than to the fixed effects 
estimates. Results of pooled estimation were presented numerically and graphically. 
Sensitivity analyses were performed in order to attain unbiased estimates and explore 
heterogenity. Comprehensive Meta-Analysis softaware version 2.2.064 2011 ( Biostat Inc., 
Englewood, NJ, USA) and SAS for Windows 9.2 (SAS Institute Inc., Cary, NC, USA) 
(macros for multiple modifier meta-regression) were used for data analyses.  
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3.6. Risk factors for POAG – protocol for observational studies 
3.6.1. Search strategy 
We searched the following electronic databases: MEDLINE using both, free interface 
of PUBMED and Ovid platform; all EBM reviews databases (Cochrane DSR, ACP Journal 
Club, HTA, DARE) accessible on OVID platform; and SCOPUS. In PUBMED, “clinical 
queries” and “related articles” functions were used to broaden the search. Search terms used 
were: “systematic review”, “meta-analysis”, “case-control”, “prospective cohort” to identify 
the study design; “glaucoma”, “open angle glaucoma” to identify the condition; “intraocular 
pressure”, ocular hypertension”, “age”, “myopia”, “race”, “gene” and a number of others to 
identify risk factors. The search strategy is depicted in Table 8. 
 
3.6.2. Study selection 
The overview included systematic reviews/meta-analyses meeting the following criteria: 
a. primary studies were prospective cohort or case-control studies; 
b. POAG disease, as defined by AAO. Both HTG and NTG variants were considered since 
there is no clear distinction between the two conditions apart from the values of IOP; 
c. assessed any (one or more) possible risk factor. 
The overview did not include: 
a. individual studies (just in case of out-dated or incomplete data from systematic reviews); 
b. other forms of reviews and reviews reported only in the abstract form; 
c. reviews dealing with secondary OAG or ACG. 
 
3.6.3. Data extraction and quality assessment 
Quality assessment of the included reviews followed the general scheme depicted in Figure 1 
and under 3.4. The specificity was the use of the MOOSE (88) checklist regarding the quality 
of reporting, designed specifically to meet the needs characteristic for observational 
(epidemiological) studies and systematic reviews dealing with such studies. Hence, MOOSE 
includes items that are common to any systematic review (e.g., reporting on definition of the 
research question, search strategy, funding sources, publication bias, characteristics of 
primary studies etc.), however, in comparison to systematic review on interventional studies it 
lacks items such as: blinding, randomization, allocation concealment and similar. Finally, it 
includes certain items specific for the methodology of epidemiological studies, in particular 
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accounting for confounding. For quality assessment of primary studies, the tool developed by 
the National Institute for Clinical Excellence (NICE) (103) was considered. 
 
3.6.4. Data synthesis/Quality of evidence 
Assessment of the quality of evidence was performed as described under 3.5. An adaptation 
of GRADE for reviews of prognostic (observational) studies that has been developed (104), 
was consulted in assigning the quality level to evidence arising from observational studies and 
systematic reviews of observational studies.   
SAS 9.2 software (SAS Institute Inc., Cary, NC, USA) was used to perform multivariate 
meta-analysis of adjusted relative risk of POAG associated with different “smoking dose” and 
for regression analysis of adjusted relative risk on “smoking dose”. Comprehensive Meta-
Analysis softaware version 2.2.064 2011 (Biostat Inc., Englewood, NJ, USA) was used  to 
perform random-effects meta-analysis of studies assessing DM as a risk factor for incident 
POAG and subgroup analysis, whereas SAS 9.2 software for meta-regression analysis. 
 
Table 8. Search strategy for systematic reviews/meta-analyses on POAG risk factors. 
1. Meta-analysis [pt] 
2 .Meta-analysis [All Fields] 
3. Systematic review [All Fields] 
28. Retinal diseases [All Fields]                                        
29. Risk factors [MeSH Terms] 
30. Risk factors [All Fields] 
4. 1 OR 2 OR 3 31. Risk [All Fields] 
5. POAG [All fields] 32. Hypertension [All Fields] 
6. Primary open angle glaucoma [All Fields] 33. Ocular hypertension [MeSH Terms] 
7. Open angle glaucoma [All Fields] 34. Ocular hypertension [All Fields] 
8. Open angle [All Fields] 35. Hypothyroidism [All Fileds] 
9. Glaucoma [All Fields] 36. Obesity [MeSH Terms] 
10. Glaucoma, open angle [MeSH Terms] 37. Genetic [All Fields] 
11. 8 AND 9 38. Cup-disc ratio[All Fields] 
12. 5 OR 6 OR 7 OR 10 OR 11 39. Cup-to-disc ratio [All Fields] 
13. 4 AND 12 40. Optic Disk [MeSH Terms] 
14. Age [All Fields] 41. Optic nerve head [All Fields] 
15. Race [All Fields] 42. Central corneal thickness [All Fields] 
16. Continental population groups [MeSH Terms] 43. CCT [All Fields] 
17. Family history [All Fields] 44. Corneal hysteresis [All Fields] 
18. Diabetes mellitus [All Fields] 45. Smoking [All Fields] 
19. Diabetes mellitus [MeSH Terms] 46. Smoking [MeSH Terms] 
20. Diabetes [All Fields] 47. Alcohols [MeSH Terms] 
21. Vascular diseases [MeSH Terms] 48. Alcohol [All Fields] 
22. Vascular diseases [All Fields] 49. Socioeconomic status [All Fields] 
23. Myopia [MeSH Terms] 50. 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 
OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 
OR 28 OR 29 OR 30 OR 33 OR 34 OR 35 OR 36 
OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 
OR 44 OR 45 OR 46 OR 47 OR 48 OR 49 
51. 13 AND 50 
24. Myopia [All Fields] 
25. Refractive errors [MeSH Terms] 
26. Refractive errors [All Fields] 
27. Retinal diseases [MeSH Terms] 
MeSH = Medical Subject Headings; pt = Publication Type. 
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3.7. Mono-compound IOP-lowering drugs in POAG/OHT – protocol for 
interventional studies 
3.7.1. Search strategy 
We searched MEDLINE (by free interface of PUBMED), COCHRANE (CDSR, DARE, 
HTA, NHS EED) and SCOPUS electronic database. The same strategy was used to search 
studies for efficacy, safety and cost-effectiveness profile of mono-compound topical IOP-
lowering drugs. Search terms used were: “systematic review”, “meta-analysis”, “RCT”, to 
identify the study design; “glaucoma”, “open angle glaucoma”, “ocular hypertension” to 
identify the condition; and “therapy”, “treatment”, “intervention”, “drug” and all individual 
names of known IOP-lowering compounds to identify interventions. The search strategy is 
depicted in Table 9. 
 
3.7.2. Study selection  
The overview included systematic reviews/meta-analyses meeting the following criteria: 
a. embraced randomized controlled trials (RCTs) of any design; 
b. POAG/OHT conditions, as defined by AAO/EGS. At least 85% of patients included in 
individual trials, or across all included primary trials suffered from POAG/OHT; 
c. the efficacy outcome was IOP, i.e., end-of-treatment IOP or IOP reduction; safety 
outcome was incidence of (any) adverse event or withdrawal due to adverse events; 
d. evaluated cost-effectiveness profile of individual treatments or comparative evaluations. 
The overview did not include: 
a. individual studies (just in case of outdated or incomplete data from systematic reviews); 
b. other forms of reviews and reviews reported only in the abstract form; 
c. reviews dealing with secondary OAG or ACG. 
 
3.7.3. Data extraction and quality assessment 
Quality assessment of the included reviews followed the general scheme depicted in Figure 1 
and under 3.4. The specificity was the use of the PRISMA (89) checklist regarding the quality 
of reporting, designed specifically to meet the needs characteristic for RCTs. Hence, PRISMA 
includes items that are common to any systematic review, but also items typical for the RCT 
methodology: e.g., blinding, randomization, allocation concealment, intention-to-treat (ITT) 
analysis. 
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3.7.4. Data synthesis/Quality of evidence 
Assessment of the quality of evidence was performed as described under 3.5. Random-effects 
pooling methods were used to recalculate data from studies in which major flaws were related 
to methods of data pooling.  
To quantify mono-compound IOP-lowering drugs, separate and combined relationship 
analyses for efficacy and tolerability/safety were performed. 
Drugs could not been ranked based on their cost-effectiveness profile as no studies were 
found. 
 
Table 9. Search strategy for systematic reviews/meta-analyses on efficacy and safety of 
topical mono-compound treatments in POAG/OHT. 
1. Meta-analysis [pt] 36. Prostanglandins, Synthetic [All fields] 
2. Systematic review [pt] 37. Latanoprost [All fields, MeSH terms] 
3. 1 OR 2 38. Travoprost [All fields, MeSH terms] 
4. Randomized controlled trials [pt] 39. Bimatoprost [All fields, MeSH terms] 
5. Clinical trial [pt] 40 .Unoprostone [All fields, MeSH terms] 
6.  4 OR 5 41. Tafluprost [All fields, MeSH terms] 
7.  3 AND 6 42. Adrenergic alpha-agonists [All fields, MeSH 
terms] 8 . Placebo [All fields, MeSH terms] 
9.  Experimental design [All fields] 43. Apraclonidine [All fields, MeSH terms] 
10. Crossover studies [All fields, MeSH terms] 44. Brimonidine [All fields, MeSH terms] 
11. Control groups [All fields, MeSH terms] 45. Epinephrine [All fields, MeSH terms] 
12.  8 OR 11 46. Dipivefrin [All fields, MeSH terms] 
13.  7 AND 12 47. Clonidine [All fields, MeSH terms] 
14. POAG [All Fields] 48. Cholinomimetics [MeSH terms] 
15. OHT [All fields] 49. Cholinergic agonists [All fields, MeSH terms] 
16. Ocular hypertension [All fields, MeSH terms] 50. Pilocarpine [All fields, MeSH terms] 
17. Primary open angle glaucoma [All Fields] 51. Carbachol [All fields, MeSH terms] 
18.  Glaucoma, Open Angle [All Fields, MeSH Terms] 52. Physostigmine [All fields, MeSH terms] 
19. 14 OR 18 53. Echothiophate [All fields, MeSH terms] 
20. Adrenergic beta-antagonists [All fields, MeSH terms] 54. Demecarium [All fields, MeSH terms] 
21. Beta adrenergic receptor blocking agent [All fields] 55. Aceclidine [All fields, MeSH terms] 
22. Timolol [All field, MeSH terms] 56. Acetylcoline [All fields, MeSH terms] 
23. Metipranolol [All fields, MeSH terms] 57. Treatment [All fields] 
24. Carteolol [All fields, MeSH terms] 58.Therapy [All fields, MeSH terms] 
25. Levobunolol [All fields, MeSH terms] 59. Pharmacological Intervention [All fields] 
26. Betaxolol [All fields, MeSH Terms] 60. Drug [All fields, MeSH terms] 
27. Pindolol [All fields, MeSH terms] 61. 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 
OR 27 OR 28 OR 29 OR 30 OR 33 OR 34 OR 35 
OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 
OR 43 OR 44 OR 45 OR 46 OR 47 OR 51 OR 52 
OR 53 OR 54 OR 55 OR 56 OR 57 OR 58 OR 59 
OR 60 
28. Befunolol [All fields, MeSH Terms] 
29. Carbonic Anhydrase Inhibitors [All fields] 
30. Carbonate dehydratase inhibitors [All fields] 
31. Acetazolamide [All fields, MeSH terms] 
32. Brinzolamide [All fields, MeSH terms] 
33. Dorzolamide [All fields, MeSH terms] 62. 19 AND 61 
34. Dichlorphenamide [All fields, MeSH terms] 63. 13 AND 62 
35. Methazolamide [All fields, MeSH terms]  
MeSH = Medical Subject Headings; pt = Publication Type. 
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4. RESULTS 
4.1. Risk factors for POAG 
4.1.1. Eligible studies 
The flow of study selection is depicted in Figure 2. The initial search retrieved 3606 records. 
All were screened by titles and abstracts and duplicate publications were removed. The 
remaining 3261 records were once again screened by titles and abstracts and 38 articles were 
retrieved in full text for the final evaluation of eligibility. At this step, 13 articles (105-117) 
were excluded (Table 10) and the remaining 25 (119-123, 136-150) were included for quality 
assessment and data synthesis. No relevant article was identified through the hand search. 
 
 
 
 
Figure 2. PRISMA flow-chart of study selection process. 
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As depicted in Figure 2, 5 of the included systematic reviews addressed either lifestyle factors 
(which are potentially modifiable) or co-morbidity factors (which, if present, could “signal” a 
potentially increased risk of glaucoma), whereas 20 addressed genetic factors, i.e., 
associations between occurrence of POAG and presence of certain genetic markers. 
Considering conceptual differences between the two groups of targeted “risk factors”, the 5 
“non-genetic” and 20 “genetic” systematic reviews are addressed separately. 
 
Table 10. Records excluded after full text reading. 
Article Reason for exclusion 
Stewart WC. The effect of lifestyle on the relative risk to develop open-angle 
glaucoma. Curr Opin Ophthalmol 1995;6:3-9. 
A narrative review. 
Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr 
Opin Ophthalmol 1996;7:93-8. 
A narrative review. 
Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN. An 
evidence-based assessment of risk factors for the progression of ocular 
hypertension and glaucoma. Am J Ophthalmol 2004;138:S19-31. 
A narrative review. 
Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and 
application. J Glaucoma 2007;16:406-18. 
A narrative review. 
Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv 
Ophthalmol 2008;53:S3-10. 
A narrative review. 
Bron A, Chaine G, Villain M, Colin J, Nordmann JP, Renard JP, Rouland JF. Risk 
factors for primary open-angle glaucoma. J Fr Ophtalmol 2008;31:435-44. 
A narrative review. 
Pasquale L, Kang JH. Lifestyle, nutrition and glaucoma. J Glaucoma 2009;18:423-
428. 
A narrative review. 
Guedes G, Tsai JC, Loewen NA. Glaucoma and aging. Curr Aging Sci 2011;4:110-
7. 
A narrative review. 
Worley A, Grimmer-Somers K. Risk factors for glaucoma: what do they really 
mean? Aust J Prim Health 2011;17:233-9. 
A narrative review. 
Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary 
open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-
analysis. Invest Ophthalmol Vis Sci 2006;47:4254-61. 
A review of glaucoma 
prevalence (not of 
interest). 
Dueker DK, Singh K, Lin SC, Fechtner RD, Minckler DS, Samples JR, Schuman 
JS.Corneal thickness measurement in the management of primary open-angle 
glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology 
2007;114:1779-87. 
Corneal thickness as an 
indicator of POAG 
management (not of 
interest). 
Ernest PJ, Schouten JS, Beckers HJ, Hendrikse F, Prins MH, Webers CA. An 
evidence-based review of prognostic factors for glaucomatous visual filed 
progression. Ophthalmology 2013;120:512-19. 
Factors predicting POAG 
progression (not of 
interest). 
Liu T, He XG. Meta-analysis on the association of Myocilin Q368X mutation and 
primary open angle glaucoma. Zhonghua Yan Ke Za Zhi 2007;43:361-6. 
Manuscript entirely in 
Chinese. 
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4.1.2. Systematic reviews addressing lifestyle and co-morbidity characteristics as 
potential risk factors for POAG 
The present work was pre-defined as an overview of reviews, hence it addressed only those 
(potential) risk factors for POAG that have been assessed through systematic reviews with 
quantitative (meta-analysis) or at least semi-quantitative (e.g., provide quantitative data but no 
meta-analysis) approach.  
Many more risk factors have been tackled over the years, some depicted already in the 
Introduction section. For example, narrative reviews not included in the present overview 
(due to the fact that they were purely narrative) (Table 10) addressed relationships between 
POAG and a variety of demographic (i.e., age, sex, race/nationality, family history of the 
disease), lifestyle (e.g., physical activity, diet, habits), environmental and co-morbidity factors 
(ocular and non-ocular).  
The quest for factors influencing POAG occurrence has been particularly focused on 
potentially modifiable factors. Recent narrative reviews (111, 113) and a large prospective 
cohort study (118) addressed several potentially modifiable variables as potential risk factors 
for POAG. As depicted in Table 11, data from individual primary studies (cross-sectional and 
case-control studies provide lower level of evidence, and prospective cohort studies provide a 
higher level of evidence), suggest:  
 
a.  for some factors that may affect IOP, there is no relevant epidemiological data that would 
allow conclusions about their relationship to POAG (e.g., physical exercise, yoga);  
b.  for some factors, there are quality data that most likely exclude them as factors affecting 
the risk of POAG (e.g., antioxidant dietary intake, tobacco smoking);  
c.  for some factors, there are quality data indicating some, but minor and apparently not 
particularly relevant effect on the risk of POAG (e.g., moderate alcohol drinking, dietary fat 
intake, hormone replacement therapy in postmenopausal women);  
d.  there is a quality but limited data suggesting excessive coffee drinking as a risk factor for 
incident POAG. 
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Table 11. Several potentially modifiable lifestyle characteristics as potential risk factors 
for POAG as assessed in recent narrative reviews (111,113) and a prospective cohort 
study (118). 
Characteristic Data Conclusions on risk of POAG 
Activities that transiently 
increase IOP e.g., weight-
lifting, certain yoga 
positions 
Although effects on IOP reproducible in 
separate studies, no data on the potential effect 
on POAG. 
Unknown. 
Activities that transiently 
reduce IOP  
Aerobic training reproducibly reduces IOP in, 
but no data on the effect on POAG. 
Unknown. 
Drinking coffee 
(caffeinated) 
Several studies indicated association of 
excessive coffee drinking and higher IOP; a 
large prospective cohort study indicated a 
greater risk of POAG with 5 cups/day 
(adjusted RR 1.6). 
Excessive coffee intake likely 
increases the risk of POAG; 
association stronger with high-
tension POAG. 
Drinking alcohol Case-control & prevalence studies conflicting 
(no, positive or negative association); a large 
prospective cohort indicated a small 
independent decrease in incident POAG with 
2 drinks/day. 
Moderate alcohol consumption 
might contribute to a lower risk 
of POAG. 
Smoking (tobacco) Case-control and cross-sectional studies 
conflicting; prospective cohorts found no 
evidence for association with POAG.  
Smoking does not seem to affect 
the risk of POAG. 
Hormone replacement 
therapy 
Several large prospective cohort studies 
indicated a greater risk of POAG with earlier 
menopause and a weak inverse effect of HRT. 
HRT (estrogen+ gestagene) 
might slightly reduce the risk of 
POAG in post-menopausal 
women. 
Dietary antioxidant intake In a large prospective cohort study with a 
detailed evaluation, carotenoids, vitamin C or 
E or specific fruits and vegetables high in 
antioxidants showed no independent 
association with the risk of POAG. 
Dietary antioxidant intake does 
not seem to affect the risk of 
POAG. 
Dietary fat intake In a large prospective cohort study, a diet 
characterized with a higher omega 6/omega 3 
fatty acids was independently associated with 
a slightly lower risk of POAG. 
Dietary fat intake might modify 
the risk of POAG. 
Indices of obesity Higher BMI repeatedly associated with higher 
IOP; but prospective cohorts found 
independent association of higher BMI and 
lower risk of POAG women (not in men); 
waist-to-hip – no association. 
In women, higher BMI is 
associated with a lower risk of 
POAG. 
IOP = Intraocular Pressure; POAG = Primary Open Angle Glaucoma;  
RR = Relative Risk; HRT = Hormone Replacement Therapy; BMI= Body Mass Index. 
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Characteristics of the 5 included systematic reviews are summarized in Table 12. Two 
reviews addressed cigarette smoking (119, 121), one addressed diabetes mellitus (120), one 
addressed myopia (122) and one (123) addressed circulating levels of homocysteine, folic 
acid, vitamin B12 and vitamin B6, as well as a single nucleotide polymorphism (SNP) in the 
gene encoding methylenetetrahydrofolate reductase (MTHFR) as potential risk factors for 
POAG. 
 
The AMSTAR check-list assessing elements of each of these systematic reviews is depicted 
in Table 13. Two reviews were assigned “N” for “comprehensive search” of the literature, 
(119, 120) since it was not performed. Two reviews were assigned “?” considering the listing 
of both included and excluded studies (122, 123). Data pooling method was inappropriate in 
one meta-analysis (119), unclear in one (120) and not performed in one systematic review 
(121). In one review (121) publication bias was not assessed, whereas one review (119) did 
not asses the scientific quality of the included studies and was not used appropriately in 
formulating conclusions. 
 
To assess quality of the body of evidence provided by these systematic reviews, we 
implemented the GRADE system modified for the purpose of prognostic studies (104).  
In this system, primary prospective cohort studies not only assessing associations but also 
possible mechanisms of risk factors are considered “phase 3 studies”, whereas prospective 
cohorts assessing associations are considered “phase 2 studies”. Systematic reviews of such 
studies have an a priori GRADE level of “high quality” (). Primary case-control 
studies are considered “phase 1 studies” and systematic reviews on such studies have an a 
priori GRADE level of “moderate quality” ().  
The level of evidence can be downgraded based on limitations/biases (individual studies), 
imprecision, inconsistency or publication bias, and up-graded on the account of a large effect 
or dose-effect (104). Cross-sectional studies are not considered relevant, since they “capture” 
prevalence and cannot serve for estimation of risk.  
Table 14 summarizes GRADE quality of evidence level for the 5 included systematic reviews. 
Table 15 summarizes main reasons for the assigned GRADE quality score. 
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Table 12. Main characteristics of included reviews (in chronological order). 
POAG = Primary Open Angle Glaucoma; OAG =Open Angle Glaucoma; 
tHcy = Total Homocysteine; SNP = Single Nucleotide Polymorphism; MTHFR = Methylenetetrahydrofolate Reductase. 
 
 
 
 
 
 
 
Ref. Objective Criteria for primary studies Studies (k), patients(n) Primary study assessments 
Bonovas 
2004a (119) 
Cigarette smoking as a risk 
factor for POAG. 
Case-control, cohort or cross-
sectional; English language. 
Cross-sectional k=4; n=9960. 
Case-control k=3; n=814. 
Quality: not assessed. Analysis: separate for current and 
past smoking. Fixed-effect pooling, all studies combined. 
Bonovas 
2004b (120) 
Diabetes as a risk factor for 
POAG.
 
Case–control, cohort or cross-
sectional; English language.  
Cross-sectional k=7; n=23000. 
Case-control k=5; n=2290.
 
Quality: confounding, case ascertainment & response 
rates. Analysis: by study type; sensitivity by quality; 
random-effects. 
Edwards 
2008 (121) 
Cigarette smoking as a risk 
factor for POAG. 
Case-control, cohort; 
outcomes: incidence or 
progression of POAG.  
Case-control k=9, n= not clear. 
Cohort k=2, n=172000.
 
Quality: 5-6 key methodological elements by study type. 
Analysis: no pooling, numerical data presented. 
Marcus  
2011 (122) 
Myopia as a risk factor for 
OAG. 
Any observational study; 
English language, OAG as an 
outcome. 
Cross-sectional k=11, n=35000. 
Cohort k=1, n=3684. 
Quality: Sanderson tool. Analysis: random-effects 
pooling, sensitivity. 
Xu  
2012 (123) 
Plasma tHcy levels; serum vit 
B12, folic acid or vit B6 levels 
or SNP C677T in the MTHFR 
gene as risk factors for POAG. 
Any observational study. All studies were case-control. 
tHyc k=12, n=546/535. 
Folic acid, B6 k=6, n=222/252. 
B3 k=3, n=109/115. 
MTHFR k=10, n=1406/1216. 
Quality: not assessed. Analysis: fixed or random-effects 
pooling; sensitivity “leave-one out” and by sample size. 
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Table 13. AMSTAR checklist scores for the included studies. 
Ref. Bonovas 2004a 
(119) 
Bonovas 2004b 
(120) 
Edwards 2008 
(121) 
Marcus 2011 
(122) 
Xu 2012 
(123) 
Design “a priori”? Y Y Y Y Y 
Duplicate selection/extraction? Y Y Y Y Y 
Comprehensive search? N N Y Y Y 
Publication status clear? Y Y Y Y Y 
List included/excluded provided?* Y Y Y ? ? 
Study characteristics provided?  Y Y Y Y Y 
Quality of studies assessed? N Y Y Y Y 
Quality accounted for conclusions? N Y Y Y Y 
Appropriate method for pooling? N ? ? Y Y 
Publication bias assessed? Y Y N Y Y 
Conflict of interest declared? Y Y Y Y Y 
AMSTAR score 7 9 9 10 10 
*All studies provided lists of included studies, but not also of excluded studies (marked by “?” – “can’t tell”). 
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Table 14. The GRADE system quality of evidence provided by the included systematic reviews. 
Ref. No studies Cohort 
studies 
Univariate Multivariate Phase Limitations Inconsistency Indirectness Imprecision Publication 
bias 
Moderate or 
large effect 
Dose 
effect 
Quality of 
evidence* +   +   
Bonovas 
2004a 
(119) 
7 0 1 2 0 1 3 0 1  (-1)  (-1)    (minor)  (-1)    
Very low 
Bonovas 
2004b 
(120) 
12 0 1 1 0 4 6 0 1  (-1)     (-1)    
Very low 
Edwards 
2008 
(121) 
11 2 0 1 0 2 8 0 1, 2  (-1)        
Moderate 
Marcus 
2011 
(122) 
11 0 0 0 0 8 3 0 --*         
    Very low 
Xu 2012 
(123) 
tHCy      
12 
0 7 5 0 0 0 0 1  (-2)  (-1)       
Very low 
 Folic acid 
6 
0 0 6 0 0 0 0 1  (-2)        
Very low 
 Vit B12   
6 
0 0 6 0 0 0 0 1  (-2)        
Very low 
 Vit B6     
3 
0 1 2 0 0 0 0 1  (-2)  (-1)       
Very low 
 MTHFR 
10 
0 0 10 0 0 0 0 1  (-1)        
Low 
*All primary studies were cross-sectional, i.e., “below phase 1”. 
(+) = positive association; () = no association; () = negative association. 
 = the review is flawed in this respect;  = the review is not flawed in this respect. 
tHcy = Total Homocysteine; MTHFR = Methylenetetrahydrofolate Reductase. 
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Table 15. Main reasons for the AMSTAR and GRADE scores. 
Bonovas 
2004a (119) 
1. No prospective cohort study. Case-control studies could be considered “phase 1” and cross-sectional should be excluded. With only 
“phase 1” studies, the a priori GRADE score is “moderate quality” (). 2. However, many limitations: a) only 3 small case-control 
studies with apparently prevalent cases (not incident); b) Only 1 employed adjustments other than age and sex (or body mass index); c) 
Fixed-effect pooling inappropriate - we found I
2
 of 43% across all studies (a random-effects meta-analysis across all studies indicated no 
association between “current smoking” and POAG: pooled OR=1.40, 0.92-2.13; p=0.133) (in contrast to report); d) Pooling case-control 
and cross-sectional studies not appropriate. A re-analysis indicated no association in cross-sectional and a mild association (based on 1 out 
of 3 studies) in case control-studies illustrating inconsistency. 3. Only Medline was searched. 4. No large effect, no dose-effect. 
Bonovas 
2004b (120) 
1. No prospective cohort study. Case-control studies could be considered “phase 1” and cross-sectional should be excluded. With only 
“phase 1” studies, the a priori GRADE score is “moderate quality” (). 2. However, several limitations: a) cases likely prevalent (not 
incident); b) 4/5 studies DM established only as “medical history; c) 1/5 no covariate adjustment, 2/5 only age & sex or body mass index; 
d) the overall estimate indicating association of DM and POAG (OR=1.5, p<0.05) pooled across the subgroups by study type. But, cross-
sectional studies should be disregarded – the 5 case-control studies yield (random-effects) OR=1.45, 0.85-2.46, p=0.173, I2=49.5%.  
3. Regardless of the “publication bias evaluation” – only one electronic database searched, hence possible omission of relevant data.  
Edwards 
2008 (121) 
1. Systematic review but without meta-analysis. 9 smaller case-control studies of poor quality, 2 prospective cohort studies, of which one 
is a pooled analysis of 2 separate cohorts, judged as “high quality”, that would correspond to “phase 2” studies. Hence, the a priori 
GRADE score is “high quality” (). 2. Data from all cohort studies consistent, however one cohort study provided no numerical 
data, just a conclusion of “no effect”. Therefore, the limited number of numerical data (pooled analysis of two cohorts) is a limitation.  
Marcus  
2011 (122) 
1. The 11 studies used to estimate myopia as a risk factor for OAG were all cross-sectional: cross-sectional studies measure prevalence, 
not incidence, hence cannot quantify “risk”. 2. The only prospective cohort study actually assessed myopia as a risk factor for incident 
glaucomatous visual field loss. 
Xu  
2012 (123) 
1. No prospective cohort study. Case-control studies could be considered “phase 1” and the a priori GRADE score is “moderate quality” 
 (). 2. However, several limitations: a) cases likely prevalent (not incident); b) There were no covariate adjustment in any of the 
primary studies. This introduced bias because (i) many factors may affect plasma/serum levels homocysteine or measured vitamins and (ii) 
many other factors may affect the risk of POAG. Hence, limitations were particularly “severe” when potential “predictors” were measure 
metabolite levels, and somewhat less severe when potential predictor was single nucleotide polymorphism. 3. Some pooled estimates were 
reported with extremely high heterogeneity (I
2 
almost 100%). 
POAG = Primary Open Angle Glaucoma; OAG= Open Angle Glaucoma; DM = Diabetes mellitus;  
GRADE = Grading of Recommendations Assessment, Development and Evaluation; OR = Odds Ratios.
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4.1.2.1. Cigarette (tobacco) smoking 
Two systematic reviews addressed cigarette smoking as a risk factor for POAG. One review 
provided very low quality of evidence (Bonovas et al. 2004) (119) based only on cross-
sectional and case-control studies and due to a number of methodological flaws at the 
systematic review level (Tables 14, 15); and the other one (Edwards et al. 2008) (121) 
provided evidence of moderate quality (Tables 14, 15).  
In fact, relevant evidence in Edwards et al. 2008 (121) comes from 2 publications addressing 
prospective cohort studies, of which one (a pooled analysis of two primary studies) provided 
numerical data. This latter report (124) was a joint analysis of data from two large prospective 
nation-wide epidemiological cohort studies in USA: the Nurses’ Health Study, embracing 
exclusively women (98% White); and Health Professionals Follow-up study, embracing 
exclusively men (98% White). We identified another similar prospective nation-wide 
epidemiological cohort study in USA that addressed cigarette smoking as a risk factor for 
POAG – the Black Women’s Healthy Study (125). 
 
In terms of quality and considering the tool developed by the National Institute for Clinical 
Excellence (NICE) (103), each of these 3 studies should be considered to be of “high quality”, 
i.e., meeting the criteria of “low risk of bias” since they:  
 included representative samples (“sampling bias” low);  
 adequately addressed non-participation and loss to follow-up (“attrition” and “non-
respondent” bias low);  
 smoking/non-smoking and the extent of exposure reliably assessed 
(“misclassification” bias low);  
 the outcome [incident  POAG] adequately verified (“observer”/“detection” bias low); 
 important confounders reliably detected and accounted for in the analysis. 
 
None of the studies found any association between smoking and the risk of POAG:  
a.  as “current smoking “ vs. never; 
b.  as “former smoking” vs. never;  
c.  as a “dose” of current or former smoking in terms of the number of cigarettes/day or as 
“pack-years” of smoking.  
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Data for this latter measure of dose-exposure are summarized in Table 16. We used them to 
perform multivariate meta-analysis (accounting for correlation of estimates from the same 
study) of adjusted relative risk of POAG associated with different “smoking dose”. Results 
are depicted at the bottom of Table 16 and demonstrate that smoking is not a risk factor for 
POAG.  
 
Table 16. Evidence base for assessment of cigarette smoking as a risk factor for POAG: 
smoking dose (as “pack-years” of smoking) and incident POAG cases (124, 125) and 
summary results of a multivariate meta-analysis of adjusted relative risks.  
Estimates are given with 95% confidence intervals. 
Population (ref.) Never 
smoked 
1-9  10-19  20-29 30 + 
White women (124) 
Person-years 
Incident POAG 
(cases) 
Adjusted relative risk* 
 
360348 
150 
1.00 (ref) 
 
154718 
49 
0.86 (0.62-1.20) 
 
106384 
28 
0.69 (0.46-1.04) 
 
80467 
22 
0.75 (0.47-1.18) 
 
88579 
37 
0.76 (0.53-1.10) 
White men (124) 
Person-years 
Incident POAG 
(cases) 
Adjusted relative risk* 
 
117802 
71 
1.00 (ref) 
 
57 913 
51 
1.49 (1.02-2.17) 
 
50 175 
27 
0.76 (0.48-1.21) 
 
15125 
12 
1.10 (0.58-2.06) 
 
3716 
3 
1.01 (0.31-3.32) 
Black women (125) 
Person-years 
Incident POAG 
(cases) 
Adjusted relative risk* 
 
272257 
201 
1.00 (ref) 
 
80139 
65 
0.94 (0.71-1.25) 
 
21172 
18 
0.72 (0.44-1.16) 
 
13715 
22 
0.93 (0.59-1.46) 
 
28888 
55 
1.08 (0.79-1.47) 
TOTAL 
Person-years 
Incident POAG 
(cases) 
 
750397 
422 
 
292770 
165 
 
177731 
73 
 
109307 
56 
 
121183 
95 
Pooled adjusted RRI 1.00 (ref) 1.06 (0.83-1.36) 0.72 (0.56-0.93) 0.91 (0.71-1.17) 0.96 (0.74-1.24) 
Across all exposures 1.00 (ref) 0.91 (0.73-1.12) 
POAG= Primary Open Angle Glaucoma; RRI= Relative Risk of Incidence. 
*In the analysis by Kang (124), the effect of smoking was assessed with adjustment for age, body mass index, hypertension, 
diabetes mellitus, African-American descent, amount of daily alcohol intake.  
In the study by Wise (125), adjustments were for age, period of follow-up, education, amount of daily alcohol intake, 
hypertension, physical activity, energy intake, diabetes and body mass index.  
We performed multivariate meta-analysis of adjusted relative risks from the three cohorts: each study provided 4 estimates, 
one for each “smoking dose”. We considered “smoking dose” as a categorical covariate and accounted for the correlation 
between estimates from the same study (cohort). We used SAS software (proc mixed) to fit the model (126). 
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We used the data also to perform a dose-response meta-analysis depicted in Figure 3. No 
“dose-dependent” trend in the adjusted relative risk of incident POAG was observed related to 
smoking. 
 
 
 
 
Figure 3. ”Dose-response” meta-analysis for smoking as a risk factor for POAG. 
Regression of adjusted relative risk on “”smoking dose” from the 3 cohort studies (size of the bubbles corresponds to weight 
assigned to each observation). 
Black dashed line presents the trend of the pooled adjusted relative risk (RR).  
Dotted line at RR=1 represents “no effect” (risk in non-smokers). 
RR (by 10 years) = change in risk of POAG by increase in “smoking dose” by 10 pack-years (with 95% confidence 
intervals). 
I2 value indicates no heterogeneity between regression coefficients in the three studies.  
We used SAS software (metadose macro) to fit the model (127). 
 
In the light of the GRADE system modified for quality assessment of evidence in the 
prognostic setting (104), all these studies belong into the category of “phase 2” studies- they 
do not “explore prognostic pathways”, but “aim to confirm/refute independent associations” 
between the presumed prognostic factor and the outcome.  
Since each (as already depicted) individual study is of high quality, it is safe to conclude that 
there is a high quality body of evidence (GRADE ) that supports a conclusion that 
smoking is not a relevant risk factor for POAG. 
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4.1.2.2. Diabetes mellitus (DM) 
Only one systematic review (Bonovas et al. 2004) (120) addressed DM as a risk factor for 
POAG. As elaborated, it provided evidence of low quality (Tables 14, 15) and is therefore not 
a basis for sound conclusions.  
We have identified, however, several large cohort studies that, among other results, provided 
evidence about the relationship between DM and incident POAG and have not been included 
in any of the systematic reviews. Their particulars are depicted in Table 17.  
 
In terms of quality (103), each of these studies should be considered to be of “high quality”, 
i.e., meeting the criteria of “low risk of bias” since they: 
 included representative samples (“sampling bias” low); 
 adequately addressed non-participation and loss to follow-up (“attrition” and “non-
respondent” bias low); 
 DM (exposure, prognostic factor) and “non-DM” (non-exposure) were adequately 
ascertained and followed-up (the risk of “misclassification” bias is low);  
 the outcome [incident POAG] was adequately verified (“observer”/“detection” bias 
low);  
 important confounders reliably detected and accounted for in the analysis. 
 
In the light of the GRADE system modified for quality assessment of evidence in the 
prognostic setting (104), all these studies belong into the category of “phase 2” studies – they 
do not “explore prognostic pathways”, but “aim to confirm/refuse independent associations” 
between the presumed prognostic factor and the outcome.  
Furthermore, each one provides consistent results that are reasonably precise, in a direct 
comparison (DM vs. non-DM), using a “direct measure”.  
Hence, each one individually provides high-quality evidence: there are no reasons for 
“downgrading” the quality level, but also, no reasons to “up-grade”, since the observed effects 
are modest and no “exposure-gradient” response was observed. 
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Table 17. DM as a risk factor for incident POAG in prospective cohort studies (by year). 
Ref. Description DM and incident POAG 
Ellis 
2000 
(128) 
A retrospective cohort based on validated administrative databases, population-based (White, Scotland, M&F). 
Inclusion: age >40 years; medically verified absence of glaucoma/OHT. Exposure: medically verified DM 
(n=6631); Non-exposure: verified absence of DM (n=166 144). Follow-up: 2 years. Outcome: age-standardized 
incidence rate (IR) of medically verified POAG. Effect measure: incidence rate ratio (i.e., relative risk). 
DM POAG: n=20,  IR= 1.1 /1000 p-y. 
Non-DM POAG: n=24, IR=0.7 /1000 p-y 
IRR=1.57 (0.99-2.48). 
Gordon 
2001 
(129) 
Prospective multicenter RCTs (70% White, USA, M&F) to evaluate the effect of treating OHT on development 
of POAG (OHTS trial). Inclusion: age >40 years, IOP 24 mmHg, no glaucoma, N=1636, followed-up for a 
median of 6 years. Of 191 patients with DM at baseline, 6 (3.1%) developed POAG. Of the 1427 patients without 
DM, 119 (8.3%) developed POAG. Effect measure: hazard ratio (i.e., relative risk). 
With adjustment for age, baseline IOP, cup-
disc ratio and corneal thickness, HR=0.37 
(0.15-0.90). No DM duration effect. 
Le 2003 
(130) 
A community-based prospective cohort study (White, Australia, M&F). Inclusion: age >40 years, medically 
excluded glaucoma. Followed-up for 5 years. N=2415. 15 developed at least probable and 39 developed possible 
OAG. A set of potential risk factors evaluated. 
Association with OAG: older age, higher 
cup-disc ratio and IOP. DM -no effect, data 
not reported. 
de 
Voogd 
2006 
(131) 
The Rotterdam study: community-based prospective cohort (White, Rotterdam, M&F). Inclusion: age 55 years, 
medically verified absence of OAG. Exposure: medically verified DM (n= 264); Non-exposure: verified absence 
of DM (n= 3573). Follow-up 5-9.5 years. Outcome: incident medically verified OAG (5/264 vs 82/3573). Effect 
measure: relative risk. 
Adjusted RR (age, BMI,, hypertension, 
follow-up, sex baseline IOP & treatment) = 
0.64 (0.25-1.64). No DM duration effect. 
Pasquale 
2006 
(132) 
The Nurses’ Health Study: nation-wide prospective cohort study (98% White, USA, only women). Inclusion: age 
30-55 years, medically verified absence of OAG. N=76 318, follow-up up to 20 years. Exposure: medically 
verified DM (32 362 p-y, n=30 incident POAG); Non-exposure: verified absence of DM (965 930 p-y, n=399 
incident POAG). Outcome: age-adjusted incidence rate of medically verified POAG. Effect measure: incidence 
rate ration (i.e., relative risk). 
Adjusted IRR (age, ethnicity, hypertension, 
BMI, physical activity, alcohol, smoking, 
family history of glaucoma) =1.82 (1.23-
2.70). No DM duration effect. 
Leske 
2008 
(133) 
The Barbados eye study: community-based prospective cohort study (Black, Barbados, M&F). Inclusion: age >40 
years, medically verified absence of definite OAG. Exposure: medically verified DM (n=536); Non-exposure: 
verified absence of DM (n=2675). Follow-up 9 years for all. Outcome: incident medically verified OAG (5.8% 
DM vs. 4.2% non-DM). Effect measure: relative risk. 
Adjusted RR (age, sex, baseline IOP and 
treatment, blood pressure and treatment, 
education, cataract) = 1.2 (0.7-1.8). No DM 
duration effect. 
Wise 
2011 
(134) 
The Black women’s health study: nation-wide prospective cohort (Black, USA, only women). Inclusion: age 21-
69, medically verified absence of glaucoma. Exposure: medically verified DM (n=1055). Non-exposure: verified 
absence of DM (n=31 294). Follow-up up to 12 years. DM: 57 medically verified incident POAG/23 488 p-y; 
non-DM: 308 incident POAG/416 171 p-y. Effect measure: incidence rate ratio (i.e., relative risk). 
Adjusted IRR (age, follow-up, education, 
alcohol, smoking, hypertension, physical 
activity, BMI) = 1.58 (1.17-2.13). No DM 
duration effect.  
POAG = Primary Open Angle Glaucoma; OAG = Open Angle Glaucoma; OHT = Ocular Hypertension; IOP = Intraocular Pressure;   
DM = Diabetes Mellitus; BMI= Body Mass Index; M= male; F= Female; OHTS =The Ocular Hypertension Treatment Study;         
RCTs = Randomized Controlled Clinical Trial; IR = Incidence Rate; IRR = Incidence Rate Ratio; HR = Hazard Ratio; RR = Relative Risk.
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Figure 4. Random-effects meta-analysis of prospective cohort studies assessing diabetes 
mellitus (DM) as a risk factor for incident POAG.  
A standard (DerSimonian-Laird) random-effects meta-analysis was performed using adjusted relative risk outcome measures: 
although slightly different by nature (relative risk, hazard ratio, incidence rate ratio), all the reported effect measures were 
measures of relative risk.  
Ln-transformed values were used for data pooling, and were then “returned” to the “raw scale” (anti-log) (RRs actually 
represent “raw” measures of the relative risk).  
We used Comprehensive Meta-analysis software. 
 
Figure 4. presents random-effects meta-analysis of the 6 studies that provided numerical data. 
Data suggest no effect of DM on the risk of incident POAG (Figure 4). However: 
 heterogeneity was appreciable (Q-statistic p=0.015, I2=65%); 
 the two studies including only women [(Pasquale 2006 (132) and Wise 2011(134)] 
each showed a higher risk in DM patients, whereas the remaining four with a 
“mixed” population indicated (i) no effect or (ii) a reduced risk (129).  
 
Therefore, we repeated the analysis separating the two studies embracing exclusively women 
from those with a mixed population. Results are depicted in Figure 5. We used two 
approaches:  
a) a standard random-effects subgroup analysis and  
b) a meta-regression analysis with “gender composition” as a covariate.  
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Both approaches demonstrated that, with adjustment for “gender composition”, the overall 
estimate remains in line with the conclusion of no effect of DM on the incidence of POAG. 
This is particularly so in studies with a mixed male-female population (Figure 5).  
As for the effect of DM in women, the two methods yielded numerically identical point-
estimates, but the regression approach yielded (expectedly) somewhat higher variance and 
wider confidence intervals resulting in “no statistical significance”, whereas subgroup 
analysis indicated a slightly increased risk of POAG in diabetic women (Figure 5). 
 
 
 
Figure 5. Diabetes mellitus (DM) as a risk factor for incident POAG: subgroup analysis 
(left) and meta-regression (right) in respect to gender composition of the 6 prospective 
cohort studies.  
The subgroup analysis is a standard random-effects (DerSimonian-Laird, DL) meta-analysis by and across the two 
subgroups, whereas meta-regression is a random-effects meta-regression using restricted maximum likelihood (REML) 
estimation.  
We used Comprehensive Meta-analysis and SAS (proc mixed) software (126). 
 
Overall, it is safe to conclude that there is a high quality body of evidence (GRADE) 
that supports a conclusion that in women, DM weakly increases the risk of POAG.  
Although data were not available separately for women and for men, it is also intuitive to 
conclude that DM does not affect the risk of POAG in men: in the four studies with “mixed” 
samples [and the one without numerical data, but reporting “no effect of DM” on the risk of 
POAG Le et al. 2003 (130)], relative risk was around unity.  
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4.1.2.3. Myopia 
One systematic review (Marcus 2011) (122) addressed myopia as a risk factor for OAG. 
Actually, the 11 meta-analyzed studies were all cross-sectional studies – hence, they recorded 
prevalence, not incidence. However, one additional case-control study and one prospective 
cohort study were included and the pooled estimate from the cross-sectional studies was in 
“the same direction” as that form the prospective cohort observations.  
The latter, prospective cohort study (135) actually assessed myopia as a risk factor for VF 
progression in POAG patients in the Rotterdam study. As already mentioned, this was a high-
quality prospective epidemiological study. Data about myopia refer to 3684 participants (both 
genders,  55 years of age) who were followed-up (ophthalmological check-ups) for at least 6 
and a maximum of 16 years (135) (total exposure 38000 p-y). With adjustment for age, sex, 
IOP, IOP treatment, family history of glaucoma and GON, high myopia was an independent 
risk factor for incident VF loss – HR = 2.31 (1.19-4.49).  
Therefore, the body of evidence about myopia as a risk factor for POAG is of low quality 
(only cross-sectional studies) and indicative but inconclusive. There is, however, moderate 
quality of evidence (only one prospective cohort study) that myopia is a risk factor for GVFD.  
 
4.1.2.4. Circulating levels of total homocysteine, folic acid, vitamin B12 and B6 and an SNP 
in the MTHFR gene as risk factors for POAG 
As depicted in Table 14 the systematic review (Xu 2012) (123) assessing total plasma 
homocysteine (tHcy) levels, serum folic acid, vitamin B12 or B6 levels as risk factors for 
POAG provided only very low quality of evidence: the embraced case-control studies did not 
account for confounders (i.e., factors affecting the levels of these analyses as well as factors 
known to be associated with POAG). Additionally, inconsistency was high considering tHcy 
and vitamin B6. Under these circumstances, the pooled estimate (12 case-control studies) 
indicating higher tHcy in patients with POAG vs. controls does not support any sound 
conclusion about the relationship between tHcy and POAG. Similarly, pooled estimates 
indicating no difference between POAG patients and controls regarding serum folic acid, 
vitamin B12 and vitamin B6 levels – provide no basis for a sound conclusion on the 
relationship between circulating levels of these vitamins and the risk of POAG.  
The limitations are less severe in the case of the evaluated SNP (C677T) in the MTHFR gene 
and the 10 embraced primary studies consistently indicated no association between this SNP 
and POAG. 
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4.1.3. Systematic reviews of genetic studies for POAG 
The genetic background of glaucoma and in particular POAG is extremely complex and has 
been intensively investigated for over 20 years.  
Three types of primary studies (apart from animal models) have been conducted: familial 
linkage studies in families with common occurrence of glaucoma that lead to identification of 
glaucoma-causative genes; population candidate-gene association studies and population 
based genome-wide association studies (GWAS).  
 
Of the 20 identified systematic reviews dealing with the genetic factors in POAG, 15 were 
meta-analyses of small “candidate-gene association” case-control studies (136-150). Their 
characteristics are summarized in Table 18. They were all published by Chinese authors.  
A recent review demonstrated an overwhelming prevalence of genetic-association meta-
analyses published from China (151) and shared common characteristics typical from 
“Chinese genetic meta-analyses”: 
 did not include GWAS study results; 
 were based exclusively on “candidate gene” case-control studies with prevalent (not 
incident) cases that frequently had less controls than cases; 
 were based on allele frequencies and not adjusted measures of associations (e.g., 
adjusted odds ratios).  
 
Overall, all these meta-analyses, although in technical sense frequently well conducted, 
provide only very low level of quality of evidence (i.e., not reliable for conclusions on 
particular genetic variants as risk factors) (151).  
Therefore, they were not further evaluated in the present work. 
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 Table 18. Main characteristics of 15 systematic reviews/meta-analyses of small “candidate-gene association” case-control studies. 
  POAG = Primary Open Angle Glaucoma; PXFG = Pseudoexfoliation Glaucoma; HTG= High Tension Glaucoma; NTG = Normal Tension Glaucoma; AH = Aqueous Humour; 
  SNP = Single Nucleotide Polymorphism; HWE = Hardy-Weinberg Equilibrium; NoS = Newcastle-Ottawa Scale; CYP1B1 = Cytochrome P450, Family 1, Subfamily B, Polypeptide; 
  MYOC = Myocilin; LOXL1 = Lysyl Oxidase-Like 1; OPTN = Optineurin; APOE = Apolipoprotein E; TNF-α = Tumour Necrosis Factor α; OPA1 = Optic Atrophy 1;  
  TP53 = Tumor Protein 53; GSTM1, GSTT1, GSTP1 = Glutathione S Transferase Polymorphisms; MTHFR= Methylenetetrahydrofolate Reductase.
Ref. Objective Criteria for primary studies Studies (k), patients(n) 
Cases/controls 
Primary study assessments 
Liu 
2008 (136) 
MYOC.mt1 SNP as a risk factor 
for POAG. 
Case-control studies. k=4; n= 835/530. Quality: case ascertainment, genotyping method. 
Analysis: Fixed-effect pooling. 
Chen  
2010 (137) 
LOXL1 SNPs as risk factors for 
XFG or POAG. 
Case-control, cohort; SNPs rs1048661, 
rs2165241 and rs3825942. 
POAG; Case-control k=9; 
n=2223 /16664. 
Quality: not assessed; HWE for each study Analysis: allelic 
distribution, overall associations, random-effects, sensitivity. 
Cheng   
2010 (138) 
OPTN SNPs as risk factors for 
POAG (HTG). 
Case-control, cohort; SNPs M98K, T34T, 
R545Q. 
Case-control k=25; 
n=4436/3838. 
Quality: blinding, genotyping method and HWE. Analysis: fixed 
and random-effects pooling; sensitivity analysis for non-HWE. 
Cheng 
2012 (139) 
SNPs in MYOC gene as risk 
factors for POAG. 
Case-control SNPs R46X, R76K, Y347Y, 
T353I, Q368X. 
k=32; n= 7128 /5259. Quality: not assessed. Analysis: fixed and random-effects 
pooling. Subgroup analysis by ethnicity. 
Dong  
2012 (140) 
SNPs in CYP1B1 as risk factors 
for POAG. 
Any type. SNPs  rs180040, rs1056836,  
rs10012, rs1056827, rs1056837, rs2567206. 
Case-control k=6; 
n=2292 / 1717. 
Quality: not assessed. Analysis: Random-effects pooling. 
 
Guo 
2012a (141) 
SNPs in OPA1 gene as risk 
factors for POAG NTG/HTG. 
Case-control, nested case-control, or cohort. 
SNPs rs166850, rs10451941. 
Case-control k=12; NTG  
n=713 /964; HTG n=1200/971.  
Quality: not assessed. Analysis: Fixed and random-effects 
pooling. Subgroup by POAG type and ethnicity; sensitivity. 
Guo  
2012b (142) 
SNPs in TP53 gene as risk 
factors for POAG. 
Case-control, nested case-control, or cohort. 
SNPs codon 72, intron 3. 
Case-control k=9; 
 n=1930/ 1463. 
Quality: not assessed. Analysis: Fixed and random-effects 
pooling; subgroup by ethnicity. 
Yu  
2012 (143) 
SNP in TNF-α –308G/A as a 
risk factor for POAG. 
Case-control. k=7;  n=1199 /1189. Quality: not assessed. Analysis: Pooled estimates by subgroups: 
ethnicity and source of controls. 
Huang 
2013 (144) 
SNPs in GSTM1, GSTT1 genes 
as risk factors for POAG. 
Case–control. k=11; n=1339 /1412. Quality: NoS scale. Analysis: Fixed or random-effects pooling; 
subgroup by ethnicity, genotyping technique, source of controls. 
Huo 
2013(145) 
SNP C677T in MTHFR gene as 
a risk factor for POAG. 
Any type. Case-control k=10; 
 n=1224 /1105. 
Quality: NoS scale. Analysis: Fixed or random-effects pooling; 
subgroup analysis by ethnicity; sensitivity by study quality. 
Lu 
2013(146) 
SNPs in GSTM1, GSTT1 genes 
as risk factors for POAG. 
Case–control. GSTM1 k=14; n=1711/1537. 
GSTT1 k=10; n=1306/ 1114.  
Quality: not assessed. Analysis: Fixed or random-effects pooling; 
subgroup by ethnicity. 
Song  
2013 (147) 
APOE polymorphisms as risk 
factors for POAG. 
Case-control studies. APOE ε2/ε3/ε4 
polymorphisms. 
k=9; n=1928/ 1793. Quality: not assessed. Analysis: Fixed or random-effects pooling; 
subgroup by ethnicity; sensitivity.  
Wang 
2013 (148) 
APOE polymorphisms as risk 
factors for POAG. 
Case-control; hospital or population-based 
APOE ε2/ε3/ε4 polymorphisms.  
k=12; n=1916 / 1756. Quality: not assessed.  Analysis: Fixed or random-effects 
pooling; subgroup by ethnicity; sensitivity “leave-one-out”. 
Xin 
2013 (149) 
TNF-α gene SNPs & TNF-α AH 
level risk factor for OAG.  
Case-control; SNPs rs1800629, rs361525, 
rs645836  or rs1799724. 
k=3 to k=14 (by SNP). Quality: not assessed.  Analysis: Fixed or random-effects 
pooling; subgroup by ethnicity; sensitivity “leave-one-out”.  
Yu  
2013 (150) 
SNPs in GSTM1, GSTT1, 
GSTP1 genes as risk factors for 
POAG. 
Case-control; English language. GSTM1 k=12, n=1908/1457;  
GSTT1 k=10 n= 1414 /1177;  
GSTP1 k=4, n=543 / 511. 
Quality: not assessed.  Analysis: Fixed or random-effects 
pooling; subgroup by ethnicity; sensitivity “leave-one-out”. 
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The next subset of “genetic” reviews addressing risk of POAG comprises three publications 
(152-154) that were not systematic reviews – rather, these were meta-analyses of data from 
GWAS studies conducted by a consortium of researchers who shared the overall data pool to 
provide pooled estimates of risks of POAG associated with several genes detected (and 
replicated) in the primary GWAS studies. All primary studies were conducted in White 
populations. General characteristics of these combined analyses are depicted in Table 19. 
 
Table 19. Main characteristics of pooled analyses of several GWAS primary studies. 
POAG = Primary Open Angle Glaucoma; OAG = Open Angle Glaucoma; SNP = Single Nucleotide Polymorphism; 
GAS7 = Growth Arrest-Specific 7; TMCO1 = Transmembrane and Coiled-Coil Domains 1; CHEK2 = Checkpoint Kinase 2; 
GWAS = Genome-Wide Association Study; ATOH7 = Atonal Homolog 7; MYOC = Myocilin; OPTN = Optineurin; 
CDC7= Cell Division Cycle 7; SALL1= Spalt-Like Transcription Factor 1; WDR36 = WD Repeat Domain 36 Gene; 
CDKN2B = Cyclin-Dependent Kinase Inhibitor 2B; SIX1= SIX Homeobox 1; SCYL1 = SCY1-Like 1; 
DCLK1 = Doublecortin-Like Kinase 1. 
 
Finally, the two last publications included in the present overview are two narrative reviews 
(155, 156) that intended to summarize and synthesise the complete knowledge on the genetic 
background of POAG. The first one was published in 2012 embracing literature published by 
the end of 2011 (a comprehensive systematic search of the literature between 1987 and end of 
2011) (155). The second and a more comprehensive one, reviewed more than 120 GWAS, 
“candidate gene” association and familial studies in humans, as well a broad variety of animal 
(e.g., knock-out and functional studies) (156). 
The common characteristics of these two reviews are that genetic background of POAG is not 
addressed only through simple associations, but also includes functional studies on the role of 
proteins coded by the assessed genetic markers and their role in pathophysiology of 
glaucoma.  
Ref. Objective Criteria for 
primary studies 
Studies (k), patients(n) 
Cases/controls 
Primary study assessments 
Ramdas 
2011a 
(152) 
SNPs in 8 genes as 
risk factors for 
POAG. 
SNPs in ATOH7, 
CDC7, SALL1, 
CDKN2B, SIX1, 
SCYL1, CHEK2, 
DCLK1. 
Nested case-control 
(incident POAG): k=1. 
Case-control  
(prevalent POAG): 
k=5;n=3161/42837. 
Quality: not assessed. 
 Analysis: pooled fixed-effect 
estimates of adjusted odds ratios 
(age and sex) from individual 
studies. 
Ramdas 
2011b 
(153) 
SNPs in 6 genes as 
risk factors for 
OAG. 
 
SNPs in MYOC, 
OPTN, WDR36, 
ATOH7, CDKN2B, 
and SIX1. 
 
Nested case-control  
(incident POAG): k=1. 
Case-control  
(prevalent POAG) k=1. 
Family-based: k=1;n=776/7426. 
Quality: not assessed. 
 Analysis: pooled data to assess 
“probability” of OAG with 
increasing number of mutant 
alleles.  
van 
Koolwijk 
2012 
(154) 
SNPs in 2 novel 
genes as risk factor 
for POAG. 
SNPs in GAS7 and 
TMCO1. 
Population based k=4 ;n=11972.  
Cohort: k=4;n=7482. 
Quality: not assessed.  
Analysis: pooled analysis of 4 
discovery and 4 replication 
GWAS studies.  
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The main findings can be summarized as follows: 
a.  There are 14 loci depicted as GLC1 (glaucoma, primary open angle), harboring 5 genes 
where a number of different mutations were found that are considered causative to POAG 
based mainly on familial linkage studies (Table 20). 
b.  Janssen et al. 2013 (156) identified further “most likely” causative genes for POAG (each 
with several SNP variants) for which, however, final confirmatory data are still lacking (Table 
21). 
To what extent, a part of understanding the pathophysiology of glaucoma, will these markers 
turn-out relevant in terms of assessing the risk of POAG remains to be seen. 
 
Table 20. Genes identified in familial linkage studies as causative to POAG (156). 
POAG = Primary Open Angle Glaucoma; JOAG = Juvenile Open Angle Glaucoma; PCG = Primary Congenital Glaucoma; 
CODA =  Cavitary Optic Disk Anomalies;  
Bold genes: POAG genes: MYOC = Myocilin; OPTN = Optineurin; ASB10 = Ankyrin Repeat and SOCS Box Containing 10; 
WDR36 = WD Repeat Domain 36 Gene; CYP1B1 = Cytochrome P450, Family 1, Subfamily B, Polypeptide; 
Italic genes: genes situated on the locus, need further research to identify the candidate POAG disease gene(s). 
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Table 21. Genes most likely causative to POAG based on GWAS and SNP-association 
studies, as identified by Janssen et al. 2013 (156). 
Gene Locus Gene Locus Gene Locus 
APOE 19q13.2 NCKAP5 2q21.2 TMTC2 12q21.31 
ATOH7 10q21.3 NTF4 19q13.33 TNF-α 6p21.3 
CAV1/CAV2 7q31.1 OPA1 3q28-q29 ZP4 1q43 
CDC7/TGFBR3 1p22 PLXDC2 10p12.31   
CDKN2B 9p21 SIX1/SIX6 14p22-23   
GAS7 17p31.1 SRBD1 2p21   
GSTM1 1p13.3 TMCO1 1q24   
APOE = Apolipoprotein E; ATOH7 = Atonal Homolog 7; CAV1/CAV2 = Caveolin 1/Caveolin 2; 
CDKN2B = Cyclin-Dependent Kinase Inhibitor 2B; TNF-α = Tumor Necrosis Factor α; 
CDC7/ TGFBR3 = Cell Division Cycle/Transforming Growth Factor, Beta Receptor III; 
GAS7 = Growth Arrest-Specific 7; GSTM1 = Glutathione S-Transferase Mu 1; OPA1 = Optic Atrophy 1;  
NCKAP5 = NCK-Associated Protein 5; NTF4 = Neurotrophin 4; PLXDC2 = Plexin Domain Containing 2; 
SIX1/SIX6= SIX Homeobox 1/ SIX Homeobox 6; SRBD1 = S1 RNA Binding Domain 1;  
TMC01 = Transmembrane and Coiled-Coil Domains 1; ZP4 = Zona Pellucida Glycoprotein 4; 
TMTC2 = Transmembrane and Tetratricopeptide Repeat Containing 2.
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4.2. Mono-compound IOP-lowering drugs in POAG/OHT 
4.2.1. Eligible studies 
The flow of study selection is depicted in Figure 6. The initial search retrieved 597 records. 
All were screened by titles and abstracts and duplicate publications were removed. The 
remaining 133 records were once again screened by titles and abstracts and 21 articles were 
retrieved in full text for the final evaluation of eligibility. At this step, 5 articles (157-161) 
were excluded (Table 22) and the remaining 16 (162-177) dealing with efficacy or safety of 
mono-compound topical IOP-lowering drugs were included for quality assessment and data 
synthesis. No study that evaluated cost-effectiveness profile of these drugs was found. No 
relevant article was identified through a hand search.  
 
Figure 6. PRISMA flow-chart of study selection of studies. 
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Table 22. Records excluded after full text reading.  
Article Reason for exclusion 
Hedman K, Alm A. A pooled-data analysis of three randomized, double-
masked, six-month clinical studies comparing the intraocular pressure reducing 
effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104. 
Not a systematic review, 
many patients with other 
types of glaucoma.  
Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, 
double-masked, six-month studies comparing intraocular pressure-reducing 
effects of latanoprost and timolol in patients with ocular hypertension. J 
Glaucoma 2003;12:463-5. 
The same material as above. 
Qian ZG, Ke M, Huang G, Zou J. Efficacy and safety of latanoprost versus 
travoprost for primary open-angle glaucoma and ocular hypertension: A meta-
analysis. Chin J EBM 2011;11:965-70. 
Manuscript entirely in 
Chinese. 
Beidoe G, Mousa SA.Current primary open-angle glaucoma treatments and 
future directions. Clin Ophthalmol 2012;6:1699-707. 
A narrative review. 
Boland MV, Ervin AM, Friedman DS, Jampel HD, Hawkins BS, Vollenweider 
D, Chelladurai Y, Ward D, Suarez-Cuervo C, Robinson KA. Comparative 
effectiveness of treatments for open-angle glaucoma: a systematic review for 
the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:271-9. 
Not only RCTs, but also non-
randomized and observational 
studies. Cited in the 
Introduction. 
 
4.2.2. Study characteristics 
Table 23 summarizes main characteristics of the 16 included reviews. They were published 
between 2000 and 2010.  
Most (10/16) were focused on both efficacy and tolerability/safety (as a secondary objective) 
(163, 165, 167-172, 174, 177), five addressed only efficacy (162, 164, 166, 173, 176) and one 
addressed exclusively local tolerability, specifically conjunctival hyperemia (175).  
Two reviews (176, 177) synthesized data using network meta-analysis, whereas the others 
were declared as “classical” meta-analyses.  
Two authors published more than one review [Cheng et al. (169, 172, 173)], even on the same 
primary studies [Van der Valk et al. (164, 176)].  
The assessed treatments and primary study selection criteria varied. One network meta-
analyses (176) aimed to assess “the most commonly prescribed mono-compounds”, whereas 
the other (177) evaluated also combination treatments, but the focus of the present overview 
is on mono-compounds. Another review (167) also addressed mono-compound and 
“adjunctive treatment” comparisons, but was included as it provided the most comprehensive 
comparison between latanoprost and brimonidine. Two further reviews tended to evaluate “all 
most commonly prescribed mono-compound treatments” (164, 173).  
Overall, the following mono-compound medications were evaluated through different modes 
of mutual comparisons: placebo; β-blockers – timolol (always as an individual compound), 
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betaxolol (as an individual compound or referred to as “other β-blockers” together with e.g., 
carteolol, levobunolol and others); α-agonists – brimonidine; carbonic anhydrase inhibitors 
(CAI) – brinzolamide and dorzolamide (as individual compounds or as “CAI as a group”); 
and prostaglandin analogues (PGAs) – latanoprost, travoprost and bimatoprost.  
Doses, formulations and dosing regimens of specific drugs differed and were sometimes 
counted as a single drug. For some drugs, data were not available. 
One review (173) explicitly included only trials in NTG patients. Considering the 
inclusion/exclusion criteria for primary studies combined with the displayed structures of the 
embraced patients (in the primary studies), it is safe to conclude that all other reviews 
assessed the treatments in the setting of (predominantly) POAG/OHT. 
Only 1/16 reviews included, among the primary studies, several non-randomized trials (i.e., 
4/16) (174). All other primary trials in all other reviews were RCTs, although 2 reviews 
intended to include also quasi-randomized trials (167, 171).  
Two reviews (166, 177) did not assess primary study quality, and the others implemented 
different tools, most commonly the Jadad score. 
 
4.2.3. Study quality 
The AMSTAR checklist and quality scores for the included reviews are depicted in Table 24. 
Some elements of scoring are self-evident (e.g., whether conflict of interest was declared or 
whether publication bias was assessed), but some require clarifications, particularly if “N” or 
“?” was assigned to an item. More details on the rational for the assigned scores are listed in 
Table 26. 
We assigned “?” to the first AMSTAR item to four reviews because there was a discrepancy 
between the declared aim and actually implemented procedures (162, 164, 173, 174). For 
example, two reviews (164, 173) intended to evaluate a large number of individual treatments 
without defining the method, but did not use network meta-analysis.  
The reason for assigning "?" to the fifth AMSTAR item in most of the reviews is the fact that 
the lists of the included but not the lists of excluded primary trials were reported.  
Next, reviews that did not consider primary trial quality when drawing conclusions from the 
meta-analytical results were assigned an "N" for the eighth AMSTAR item (165, 166, 169, 
175-177).  
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Table 23. Main characteristics of the included reviews (in chronological order). 
Ref. Objective Criteria for primary studies Studies (k), patients (n) Primary study assessments 
Einarson 
2000 
(162) 
Indirectly compare LAT with BRIM 
for IOP reduction in POAG. 
RCT, English language. POAG with IOP 
≥20 mmHg. At least one arm includes LAT 
or BRIM. Peak, trough or diurnal IOP; 
duration 3-12 months. 
k=9 (DB, parallel), none comparing LAT to 
BRIM. LAT: k=6; BRIM: k=3. 
Quality: Jadad score. Efficacy: IOP vs. baseline 
and % with controlled IOP for LAT and BRIM as 
individual treatments. Safety: not assessed. 
Random-effects. 
Zhang 
2001 
(163) 
Compare LAT with TIM for IOP 
reduction and safety in OAG/OHT. 
RCT. OAG/OHT. Directly compare LAT 
and TIM. 
k=11 (10 DB, 1 SB; 7 parallel, 4 cross-over); 
n = 1256; 410 POAG, 465 OHT, 137 OAG. 
Quality: Jadad score. Efficacy: IOP vs. baseline at 
4 time-points. Safety: local, systemic, AE 
withdrawals. Random or fixed-effect. 
van der 
Valk 2005 
(164) 
Estimate IOP reduction at peak and 
trough by the most commonly 
prescribed mono compounds in 
POAG-HTG/OHT. 
 
RCT, English, German, Dutch or French 
language. POAG-HTG or OHT. Compare 
(any): Placebo; TIM 0.5% bid; BET 0.5% 
bid; BRIM 0.2% bid; DORZ 2.0% bid; 
BRINZ 1.0% tid; LAT 0.005% qd; TRAV 
0.004% qd; BIMA 0.03% qd. 
k=27, n=6053 for peak and 6861 for trough 
IOP. Placebo k=3; BET k=5; TIM k=15; 
BIMA k=6; LAT k=12; TRAV k=5; BRIM 
k=4, BRINZ k=1, DORZ k=6. 
Quality: Delphi score. Efficacy: absolute and 
relative IOP vs. baseline for peak and trough for 
each individual treatment;1-6 months pooled as 1 
time-point. Safety: not assessed. Random-effects. 
 
Li  
2006 
(165) 
Compare TRAV with LAT, BIMA 
and TIM for IOP reduction and safety 
in OAG/OHT. 
RCT, English or Chinese language. OAG or 
OHT; Compare TRAV vs. other PGA or 
TIM. Report IOP or AEs. 
k=12 (parallel, 8 DB, 4 SB);  
n=3048, 2060 POAG, 840 OHT, 114 other. 
TRAV 0.004% vs. TIM k=4; TRAV 0.004% 
vs. BIMA k=5; TRAV 0.004%  vs. LAT k=5. 
Quality: Cochrane tool for risk of bias. Efficacy: 
IOP vs. baseline; 8/12 trials ITT analysis. Safety: 
local. Random or fixed-effect. 
Denis  
2007 
(166) 
Compare TRAV with LAT and 
BIMA for IOP reduction in 
OAG/OHT. 
RCT, parallel, English of French language. 
OAG or OHT. Any comparison of TRAV, 
LAT, BIMA; Report on IOP. 
k=9; n=1318, 378 OHT, 919 OAG, 21 other. 
Comparing all 3 (three-arm trials) k=2. 
Comparing any two (two-arm trials) k=7. 
Quality: Not assessed. Efficacy: IOP at study end 
(average) and % responding for each individual 
treatment. Safety: Not assessed. Random-effects. 
Fung  
2007 
(167) 
Compare LAT with BRIM for IOP 
reduction and safety in OAG/OHT. 
RCT or quasi-RCT. OAG/NTG/OHT. 
Compare LAT to BRIM; adjunctive 
treatment possible. Duration ≥1 month. 
Reports on efficacy or safety. 
k=15 (all RCT, 11 parallel, 4 cross-over; 4 
DB, 7 SB, 4 unknown).  n=1824, 1299 OAG, 
390 OHT, 64 NTG, 60 other. Mono-treatment 
k=9; adjunctive treatment k=6. 
Quality: Allocation concealment, blinding and IOP 
measurement method. Efficacy: IOP vs. baseline, 
peak or diurnal. 5/15 trials ITT analysis. Safety: 
local and systemic. Random-effects. 
Aptel  
2008 
(168) 
Compare BIMA, LAT and TRAV for 
IOP reduction and safety in 
POAG/OHT. 
RCT, DB. POAG or OHT >90%. Compare 
LAT 0.005%, TRAV 0.004% or BIMA 
0.03% 1 drop/day between 6 and 10 PM. 
Report diurnal IOP and conjunctival 
hyperaemia. Duration 1-6 months. 
k=8 (parallel). n=1610; 
LAT vs BIMA k=4; TRAV vs BIMA k=2; 
LAT vs TRAV k=1; LAT vs TRAV vs BIMA 
k=1. 
Quality: Jadad score. Efficacy:  IOP vs. baseline 
(4 daily values: 8 AM, 12 noon, 4 PM, 8 PM 
separately), all trial duration as one time-point. 
Safety: conjunctival hyperemia. Fixed-effect. 
Cheng  
2008 
(169) 
Compare BIMA with LAT for IOP 
reduction and safety in 
glaucoma/OHT. 
RCT. Glaucoma or OHT, NTG excluded. 
Directly compare LAT and BIMA. Report 
on IOP reduction or % patients achieving the 
target IOP. 
k=13 (5 DB, 8 SB, 10 parallel, 3 cross-over). 
n=1302; 754 POAG, 327 OHT, 211 other. 
LAT 0.005% vs. BIMA 0.03%; 1 x evening  
 
Quality: Jadad score. Efficacy:  IOP vs. baseline 
(morning/diurnal) or % patients achieving IOP≤17; 
3 different time-points. Safety. Local. Random-
effects. ITT basis. 
Hodge  
2008 
(170) 
Compare PGAs with BRIM and 
DORZ for IOP reduction and safety in 
OAG/OHT. 
RCT, English language. OAG/OHT, ACG 
excluded. Compare PGAs and BRIM or 
DORZ. 
k=7 (parallel); n=1131, 418 POAG, 555 
OHT, 60 other, 98 unknown. LAT vs BRIM 
k=3 (+1 safety); LAT vs DORZ k=3. 
Quality: Jadad score. Efficacy:  IOP vs. baseline 
at 3 months. 2/7 trials ITT. Safety: local, AE 
withdrawals. Random or fixed-effect. 
Continues on the next page 
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     Ref. Objective Criteria for primary studies Studies (k), patients (n) Primary study assessments 
Loon  
2008 
(171) 
Compare TIM with BRIM for IOP 
reduction and safety in glaucoma. 
RCT, pseudo-RCT. Glaucoma. Directly 
compare TIM 0.5% to BRIM 0.2%. Report 
on IOP and safety, ≥ 1 month. 
k=10 (all RCT, 7 DB,1 open, 2 unknown); 8 
used for quantitative synthesis; n= 2387, 1442 
OAG, 877 OHT, 68 other.  
 
Quality: Allocation concealment, blinding, 
withdrawals, ITT/LOCF. Efficacy:  IOP vs. 
baseline (peak or mean). 8/10 trials ITT analysis. 
Safety: local, systemic. Random-effects.. 
Cheng 
2009a 
(172) 
Compare TRAV and LAT for IOP 
reduction and safety in OAG/OHT. 
RCT. OAG/OHT with lOP >21 mmHg, 
NTG/ACG excluded. Compare TRAV 
0.004% to LAT 0.005% once daily. Report 
on IOP at 9 AM and/or 5 PM. 
k=17 (9 DB, 8 SB, 13 parallel, 4 cross-over), 
n=1491; 966 OAG, 379 OHT, 146 other. 
Quality: Jadad score. Efficacy:  IOP vs. baseline 
(separately 9 AM and 5 PM) at 5 different time-
points. 6/17 trials ITT analysis. Safety: local and 
AE withdrawals. Random-effects. 
Cheng 
2009b 
(173) 
Estimate IOP reduction by the most 
commonly prescribed mono 
compounds in NTG. 
 
RCT, any language; Advanced NPG. 
Compare (any): Placebo, BET 0.25/0.5% 
bid, TIM 0.5% bid, DORZ 0.2% tid, BRINZ 
1.0% tid, BRIM 0.2% bid, LAT 0.005% qd, 
TRAV 0.004% qd, BIMA 0.03% qd. Report 
absolute and relative IOP reduction. 
k=15 (5 DB, 6 SB, 4 open, 5 parallel, 10 
cross-over); n= 450. 
 
 
Quality: Delphi score. Efficacy: absolute and 
relative IOP vs. baseline for peak, trough and 
diurnal curve for each individual treatment (0.5-2 
months) as 1 time-point. Safety: Not assessed. 
Random-effects. 
Ejawo  
2009 
(174) 
Compare BIMA, LAT and TRAV for 
IOP reduction and safety in 
POAG/OHT. 
RCT, excluded dose-finding, cross-over and 
short-term. POAG/OHT. Any comparison 
between TRAV 0.004%, LAT 0.005% and  
BIMA 0.03%. Report on IOP and AEs. 
k=16 (4 non-RCT, unknown blinding), 
n=2674, 1705 POAG, 727 OHT, 242 other. 
TRAV vs. LAT k=9; TRAV vs. BIMA k=8; 
LAT vs. BIMA k=8; >2 arms k=5. 
Quality: randomization, allocation concealment, 
ITT, blinding. Efficacy: IOP (morning) at study 
end (3-12 months), 6/16 trials ITT analysis. Safety: 
conjunctival hyperemia. Random-effects. 
Hornubia 
2009 
(175) 
Compare LAT with BIMA and 
TRAV for conjunctival hyperaemia in 
glaucoma/OHT. 
RCT, English language. Glaucoma/OHT. 
Any comparison between LAT, BIMA or 
TRAV reporting on conjunctival hyperemia. 
k=13 ( 10 parallel, 3 cross-over); n= 2222; 
1364 OAG, 678 OHT and 180 other. LAT vs. 
BIMA k=8, LAT vs. TRAV k=6, 3 arms k=1 
Quality: Jadad score. Efficacy: Not assessed. 
Safety: Conjunctival hyperaemia. Fixed and 
random-effects. 
v.d.Valk 
2009 
(176) 
Estimate IOP reduction at peak and 
trough by the most commonly 
prescribed mono compounds in 
POAG-HTG/OHT by MTC. 
 
RCT, English, German, Dutch or French 
language. POAG-HTG or OHT. Compare 
(any): Placebo; TIM 0.5% bid; BET 0.5% 
bid; BRIM 0.2% bid; DORZ 2.0% bid; 
BRINZ 1.0% tid; LAT 0.005% qd; TRAV 
0.004% qd; BIMA 0.03% qd. 
k=27, n=6053 for peak and 6861 for trough 
IOP. Placebo k=3; BET k=5; TIM k=15; 
BIMA k=6; LAT k=12; TRAV k=5; BRIM 
k=4, BRINZ k=1, DORZ k=6. 
Quality: Delphi score. Efficacy: absolute and 
relative IOP vs. baseline for peak and trough 
using timolol as a reference;1-6 months pooled as 1 
time-point. Safety: not assessed. Random-effects. 
Orme  
2010 
(177) 
Compare IOP reduction and 
conjunctival hyperemia of different 
treatments in POAG/OHT by MTC. 
RCT, English language, ≥ 20 patients. 
POAG/OHT, excluded ACG & secondary. 
Include a PGA in at least one arm.  
MTC Efficacy: k=18; n=2943; MetaReg 
Efficacy k=73, n=11519; MTC Safety: k=72. 
Evaluated treatments: TIM, LAT- TlM, CAI-
TIM, TRAV-TIM, BIMA, TRAV, LAT, CAI, 
Other UC, Other β-blockers, Placebo.  
Quality: Not assessed. Efficacy: MTC for 3-month 
outcomes - absolute IOP; predicted probability of 
IOP <20 mmHg or ≥20% reduction vs. baseline 
and NNTB vs. timolol. Safety: MTC of % patients 
with conjunctival hyperemia and NNTH vs. 
Placebo. Random-effects. 
RCT = Randomized Controlled Trial; DB = Double Blind; SB = Single Blind; ITT = Intention–To–Treat; LOCF = Last Observation Carried-Forward; PP = Per-Protocol; NNTB = Number 
Needed To Treat To Benefit; NNTH = Number Needed To Treat To Harm; MetaReg = Meta-Regression Analysis; MTC = Random-Effects Mixed Treatment Comparisons (or Network Meta-
Analysis); POAG = Primary Open Angle Glaucoma; OHT = Ocular Hypertension; NTG = Normal Tension Glaucoma; OAG = Open Angle Glaucoma; PDG = Pigment Dispersion Glaucoma; 
ACG = Angle Closed Glaucoma; HTG = High Tension Glaucoma; IOP = Intraocular Pressure; AEs = Adverse Events;  
PGAs = Prostaglandin Analogues; CAI = Carbonic Anhydrase Inhibitors; UC = Unfixed Combinations; LAT = Latanoprost; BIMA = Bimatoprost; TRAV = Travoprost; BRIM = Brimonidine; 
TIM = Timolol; BET = Betaxolol; DORZ = Dorzolamide; BRINZ = Brinzolamide; qd = Once a Day; bid = Twice a Day; tid = Three Times a Day. 
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Table 24. Quality of the included reviews based on the AMSTAR (91) checklist.  
Ref. Einarson 
2000 
(162) 
Zhang 
2001 
(163) 
v.d. Valk 
2005 
(164) 
Li 
2006 
(165) 
Denis 
2007 
(166) 
Fung 
2007 
(167) 
Aptel 
2008 
(168) 
Cheng 
2008 
(169) 
Hodge 
2008 
(170) 
Loon 
2008 
(171) 
Cheng 
2009a 
(172) 
Cheng 
2009b 
(173) 
Ejawo 
2009 
(174) 
Hornubia 
2009 
(175) 
v.d.Valk 
2009 
(176) 
Orme 
2010 
(177) 
 
Design “a priori”? ? Y ? Y Y Y Y Y Y Y Y ? ? Y Y Y 
Duplicate selection/extraction? Y Y Y Y N Y Y Y Y Y Y Y Y Y Y# ? 
Comprehensive search? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y# Y 
Publication status clear? Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y# Y 
List included/excluded provided?* ? ? ? Y ? ? ? Y ? ? ? ? ? Y ? Y 
Study characteristics provided? Y Y Y Y Y Y Y Y Y Y Y Y Y  Y Y# Y 
Quality assessed? Y Y Y Y N Y Y Y Y Y Y Y Y Y Y# N 
Quality accounted for conclusions? Y Y Y N N Y Y N Y Y Y Y Y N N N 
Appropriate method for pooling? N N N ? N Y ? ? Y N N N Y ? ? Y 
Publication bias assessed? N N Y Y Y Y Y N N Y Y Y Y Y ? Y 
Conflict of interest declared? Y N Y Y Y Y Y Y Y N N Y Y Y Y Y 
AMSTAR score 7 7 8 9 6 10 9 8 9 8 8 8 9 9 7 8 
Y = yes; N = No; ? = can’t tell; NA = not applicable. 
*All reviews reported on included studies, but only 3 reported also on excluded studies. Hence, most reviews failed to meet this quality criterion. 
#Described in the previous publication [v.d. Valk 2005 (164)].
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However, the major flaws were related to methods of data pooling, i.e., statistical analysis 
(more details are provided in Table 26): 
 Only four reviews (167, 170, 174, 177) used fully correct methods and were assigned 
a “Y”.  
  Five reviews (165, 168, 169, 175, 176) were assigned a “?” primarily due to the fact 
that fixed and random-effects data pooling were used alternatively without clear 
criteria/justification. 
The relevance of inadequate pooling is best illustrated by the example of Loon et al. 2008 
(171) which was, because of that, assigned an “N”. This review embraced 8 RCTs comparing 
timolol to brimonidine. The assessed outcome was the amount of IOP drop from baseline to 
the end of trials (higher values represented a more pronounced IOP reduction). Fixed-effect 
meta-analysis was used to pool the data across subgroups of trials, i.e., for 5 trials with 100 
patients and more, for 3 trials with <50 patients, and an overall estimate (“across subgroups”) 
was produced as illustrated in Figure 7.  
The analysis indicated that in the larger trials there was a statistically significantly greater 
reduction in favor of brimonidine (pooled treatment difference 0.65, p<0.001), while the 
difference in smaller trials was smaller (Figure 7). Overall, the analysis indicated a 
significantly greater IOP reduction with brimonidine – difference 0.46 mmHg, p<0.001 
(Figure 7). It should be noted that in both subgroups of trials and overall, there was 
considerable heterogeneity (high I
2
 values, p<0.001 in the Q-test of heterogeneity) (Figure 7).  
 
 
 
 
 
 
 
 
 
Figure 7.  Forrest plot and fixed-effect meta-analysis of 8 trials comparing timolol to 
brimonidine for IOP reduction taken from Loon et al. 2008 (171). 
The analysis was performed in subgroups of trials by size: larger (100 or more patients) and smaller (<50 patients), and 
overall. The results indicate a significantly greater reduction with brimonidine in larger trials and overall. 
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We recalculated the data displayed in Figure 7 using random-effects pooling which is a 
standard procedure for pooling data from trials that differ in design characteristics, and 
particularly when there is any evidence of heterogeneity. 
As shown in Figure 8, re-analysis of data from Figure 7 using the appropriate, random-effects 
pooling method clearly demonstrated no significant difference between brimonidine and 
timolol in IOP reduction, based on the trials included in the review by Loon et al. 2008 (171). 
 
 
 
 
 
 
 
 
Figure 8. Summary of random-effects meta-analysis of data from Loon et al. 2008 (151) 
displayed in Figure 7.  
Presented are pooled estimates for the subgroup of large trials, small trials and overall. It should be noted that by random-
effects method no difference is observed between brimonidine and timolol – regardless of the trial size (and overall). 
Heterogeneity is very high. 
 
The major reason for assigning an “N” (Table 24) to the reviews by Einarson 2000 (162), van 
der Valk 2005 (164), Denis 2007 (166) and Cheng 2009b (173) was the use of explicitly 
erroneous data pooling method that resulted in non-randomized comparisons between 
treatments: instead of pooling treatment differences (arising from randomized settings, i.e., 
RCTs), they pooled values for individual treatments across trials and then compared these 
pooled estimates. This approach has been called “naïve indirect comparisons” and is prone to 
bias, inadequate numerical estimates (“far from true treatment differences”) and is no better 
than using data from non-randomized or observational settings. Consequently, it is strongly 
discouraged (178).  
Both the review by Zhang et al. 2001 (163) and by Cheng et al. 2009b (173) used an 
erroneous method for calculation of SD of change in IOP vs. baseline, i.e., they treated it as if 
it came from independent samples (i.e., SD for difference between two independent groups of 
subjects) disregarding the correlation between measurements taken in the same patients (at 
baseline and at same time-point post-baseline, e.g., at the end of the trial).  
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Let us assume that the SD of baseline IOP is 6 mmHg and of end-of-trial IOP is also 6 
mmHg. The SD of change in IOP, if calculated disregarding correlation, is 6 mmHg. 
However, if there is correlation (as one would expect), the estimate differs: assuming a high 
correlation with a correlation coefficient of 0.8, the standard deviation of IOP change is 3.8 
mmHg, and assuming a low correlation, say correlation coefficient of 0.2, the standard 
deviation of IOP change is 7.6. Both estimates are clearly different from 6, and this then 
reflects on the estimated treatment differences.  
Zhang et al. 2001(163) made another methodological error – for the meta-analysis, they did 
not use “raw” IOP change data (in mmHg), but “% change in IOP”, which they calculated as 
“IOP reduction/IOP baseline” (where reduction is IOP mean at the end – IOP mean at 
baseline). This is an inadequate approach – “% change vs. baseline” can only be calculated if 
all individual patients data for baseline and end-of-treatment are available as: 
 
                                
  
                  
        
     
 
      
 
Where i = represents an individual patient in a trial and n= total number of patients in a trial. 
Hence, “% change” can be meta-analyzed only if reported by each individual study, or if all 
individual data are available, but not if determined from summary statistics. 
 
A further methodological error by Zhang et al. 2001 (163) was determination of SD of the “% 
change vs. baseline” since it was determined as “SD of change (in mmHg)/IOP at baseline”. 
Standard deviation of “% change vs. baseline” is actually a standard deviation of a ratio, since 
“% mean change” is a ratio [(baseline-end)/baseline)], and is calculated as: 
 
   
 
 
  
 
 
     
     
      
 
 
   
     
      
 
 
 
 
Assume that baseline IOP is 26 mmHg with SD 7. End-of study IOP is 17 mmHg and mean 
change is 9 mmHg with SD 6. If calculated as SD change /IOP baseline, then SD of % change 
would be 6/26=0.23, or 23%. Properly calculated, the result is 0.25 or 25%.
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4.2.4. Quality of evidence 
The level of quality assigned within the GRADE framework to each of the 16 included 
reviews (where each one is a “body of evidence”) is depicted in Table 25.  
The GARDE quality level assigned to a review was based on its quality, but also on the 
properties of the primary trials included in the review, their quality, number of patients, 
precision of the estimates within the review as well as on the type of treatment comparison 
within a review (direct, indirect or mixed).  
The highest level of quality of evidence achieved was “moderate” and was attained by 5 
reviews (Table 25): Li et al. 2006 (165), Fung et al. 2007 (167), Aptel et al. 2008 (168); 
Hornubia et al. 2009 (175) and Orme et al. 2010 (177). More detailed reasons why these 5 
reviews were downgraded to “moderate” quality, as well as the reasons for quality grades 
assigned to other reviews are depicted in Table 26 at the end of this section. 
Li et al. 2006 (165) and Aptel et al. 2008 (168) were downgraded by 1 for imprecision 
because certain comparisons between pairs of evaluated treatments were based on only 2-3 
primary trials and/or a small number of patients resulting in very wide confidence intervals.  
Fung et al. 2007 (167) and Hornubia et al. 2009 (175) were downgraded by 1 for 
limitations/bias since they included only a few double-blind trials and intent-to-treat analysis 
in primary studies was low or unknown.  
In addition, the unit-of-analysis issue (unclear handling of multi-arm and cross-over trials) 
was highly suspected in Hornubia et al. 2009 (175).  
Orme et al. 2010 (177) was downgraded by 1 for indirectness since some of the comparisons 
in the assessed network were predominantly or exclusively indirect. 
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Table 25. Quality of evidence provided by individual reviews based on the GRADE evaluation system. 
Ref. Einarson 
2000 
(162) 
Zhang 
2001 
(163) 
v.d. Valk 
2005 
(164) 
Li 
2006 
(165) 
Denis 
2007 
(166) 
Fung 
2007 
(167) 
Aptel 
2008 
(168) 
Cheng 
2008 
(169) 
Hodge 
2008 
(170) 
Loon 
2008 
(171) 
Cheng 
2009a 
(172) 
Cheng 
2009b 
(173) 
Ejawo 
2009 
(174) 
Hornubia 
2009 
(175) 
v.d.Valk 
2009 
(176) 
Orme 
2010 
(177) 
Limitations/bias -1 -1 -1 Minor -2 -1 Minor -1 -1 -1 -1 -1 -2 -1 -1 Possible 
Inconsistency Minor -1 Minor Minor -1 Minor Minor -1 Some -1 Minor Minor Some No Minor No 
Indirectness -2 Direct -2 Direct -2 Direct Direct Direct Direct Direct Direct -2 Direct Direct -1 -1 
Imprecision Minor Minor Minor -1 Minor Minor -1 Some -1 Minor -1 Some Minor Minor Minor Minor 
Publication bias Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Unlikely Possible Unlikely 
Quality of body 
of evidence* 
+ 
Very low 
++ 
Low 
+ 
Very low 
+++ 
Moderate 
+ 
Very low 
+++ 
Moderate 
+++ 
Moderate 
++ 
Low 
++ 
Low 
++ 
Low 
++ 
Low 
+ 
Very low 
++ 
Low 
+++ 
Moderate 
++ 
Low 
+++ 
Moderate 
*This is judged in respect to the primary research question posted in each review. See Materials and Methods for the GRADE system levels of quality of evidence.
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Table 26. Main reasons for downgrading the AMSTAR and GRADE scores.  
Einarson 
2000 
(162) 
1. The declared aim was to indirectly compare latanoprost to brimonidine. However, erroneous data pooling and meta-analysis methods were used: instead of an 
indirect comparison through a network (which was possible), IOP vs. baseline was pooled for the two treatments across trials that compared them to a variety of 
other treatments, and a non-randomized comparison was performed. 2. Seemingly erroneous calculation of variance of “within-treatment” IOP vs. baseline. 
Zhang 
2001 
(163) 
1. Erroneous calculation of variance of “within-treatment” IOP vs. baseline and of variance of “% vs. baseline” (86)*. 2. When Q test “not significant” fixed-
effect pooling. However, with a small number of trials at time points with the largest treatment differences, Q-test p-value was>0.1, but we calculated I
2
 values 
(2)
#
 of 56%, 20% and 34.5%, respectively. Consequently, random-effects pooling would have been more appropriate for generation of valid estimates. 3. 
Handling of cross-over trials not clearly stated (possible “unit-of-analysis” issue). 4. A comprehensive overview of local and systemic safety reported in 
individual trials was presented. However, data pooling likely inappropriate: many “zero event cells”/”no event trials” should not be pooled as random-effects 
relative risk or risk difference (87). 
v.d. Valk 
2005 
(164) 
1. Erroneous data pooling and meta-analysis method (86)*: IOP vs. baseline for individual treatments instead of between-treatment differences; relative 
treatment “positioning” based on non-randomized comparisons. 2. Erroneous calculation of variance of “within-treatment” IOP vs. baseline and of variance of 
“% vs. baseline” (86)*.  
Li 
 2006 
(165) 
1. Several trials with >2 arms treated as if assessing independent pair-wise comparisons (“unit-of-analysis” issue). 2. Time points that were much apart (1 week 
to 12 months) were pooled together (no account on trial duration) and “type” of IOP (diurnal, peak or through) not declared. This could have influenced the 
estimated treatment differences. 3. Some safety estimates based on only few trials with some “zero event cells”. 
Denis 
2007 
(166) 
1. Erroneous data pooling and meta-analysis method (86)*: IOP at end of treatment for individual treatments instead of between-treatment differences; relative 
treatment “positioning” based on non-randomized comparisons. 2. Blinding and ITT analysis by trial not addressed. 3. Inclusion of secondary OAG not stated. 
Fung  
2007 
(167) 
1. Only 4 double-blind trials, only 5 with ITT analysis. 2. Still high heterogeneity in subgroup (by trial duration) analysis. 3. A comprehensive display of adverse 
events, but for some high heterogeneity, for others only a few trials and “zero event cells/no event trials” (random-effects risk difference not appropriate effect 
measure) (87). 
Aptel  
2008 
(168) 
1. Fixed-effect pooling although Q test for some outcomes p<0.05. For others, Q test p>0.1, but with only a few trials. E.g., for two largest treatment differences 
we calculated I
2
 values (2)
 #
 of 44%, respectively (random-effects might have been more appropriate). 2. One 3-arm trial – unclear handling (“unit-of-analysis” 
issue?). 3. Latanoprost vs. travoprost only in 1 trial. 4. No record on ITT analysis by trial. 6. Individual trial data on conjunctival hyperaemia not displayed. 
Cheng 
2008 
(169) 
1. Erroneous calculation of variance of “within-treatment” IOP vs. baseline and of “% vs. baseline” (86)*. 2. Stated ITT analysis but, as detected through other 
reviews, at least 5 RCTs did not apply ITT analysis. While this can be corrected at the meta-analytical level for binary outcomes, a correction is impossible for 
continuous outcomes. 3. Efficacy treatment difference inconsistent for morning and diurnal IOP, as well as for “% achieving target”. 4. Handling of cross-over 
trials not stated (possible “unit-of-analysis” issue). 5. Comprehensive presentation of adverse effects, but some only on few trials with “zero event cells” 
(random-effects risk difference not an appropriate effect measure) (87). 
Continues on the next page 
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Hodge 
2008 
(170) 
1. 2/4 trials comparing efficacy of latanoprost to brimonidine and 3/3 comparing it to brinzolamide - low quality (Jadad score 2). 2. Only 1 study for each 
comparison was based on ITT analysis. 3. All trials for latanoprost vs. dorzolamide on diurnal IOP, latanoprost vs. brimonidine on diurnal and morning mixed 
together (might have affected the estimates). 4. Safety outcomes assessed on only a few trials. Individual trial data not displayed, but likely some “zero event 
cells”/”no event trials” (risk difference not appropriate effect measure) (87). 
Loon  
2008 
(171) 
1. Erroneous data pooling: efficacy subgroup analysis by trial size using fixed-effect despite very high I
2
 concluded treatment difference in large trials. Re-
calculated by random-effects – no difference I. 2. Erroneous weighing in subgroup analysis by trial duration (relative weight distributed as if there were 16 trials). 
3. Unclear meta-regression procedure (could not be replicated). 4. Safety outcomes assessed on trials with high prevalence of “zero event cells/trials” (random-
effects relative risk not appropriate effect measure) (87). 
Cheng 
2009a 
(172) 
1. Erroneous calculation of variance of “within-treatment” IOP vs. baseline (86)*. 2. Stated ITT, but 11/17 included RCTs did not apply ITT analysis. While 
this can be “corrected” at the meta-analytical level for binary outcomes, a correction is impossible for continuous outcomes. 3. Handling of cross-over trials not 
stated (possible “unit-of-analysis” issue). 4. No sensitivity analysis in respect to ITT and blinding. 4. Inconsistent results for diurnal and afternoon IOP reduction.  
5. A comprehensive display of adverse events, but some assessed on only a few trials. Unknown prevalence of “zero event cells”/”zero event trials” (random-
effects relative risk not appropriate effect measure) (87). 
Cheng 
2009b 
(173) 
1. Erroneous data pooling and meta-analysis method (86)*: IOP vs. baseline for individual treatments instead of between-treatment differences; relative 
treatment “positioning” based on non-randomized comparisons. 2. Erroneous calculation of variance of “within-treatment” IOP vs. baseline and of variance of 
“% vs. baseline” (86)*. 
Ejawo 
2009 
(174) 
1. Aimed to include only RCTs, but 4/16 trials were non-randomized. 2. The 5 3-arm trials handled as if independently assessing pair-wise comparisons - “unit-
of-analysis” issue. 3. No reference to individual study blinding, randomization and ITT analysis. 4. Individual study data on conjunctival hyperaemia not 
displayed. 
Hornubia 
2009 
(175) 
1. One 3-arm trial treated as if assessing independent pairwise comparisons – “unit-of-analysis” issue. 2. Unclear handling of cross-over trials (further “unit-of-
analysis problem”?). 3. ITT approach and blinding by study not addressed. 
v.d.Valk 
2009 
(176) 
1. A network (“multiple-treatment”) meta-analysis based on previously identified (van der Valk et al. 2005) RCTs – likely erroneous (as in the previous 
publication) calculation of variance of “% vs. baseline” .2. No up-dated trial search. 3. Ranking based on individual treatment difference vs. timolol, but a 
limited number of direct comparisons for many treatments in the network. 4. Traditional meta-analysis not performed. 5. ITT analysis and blinding by trial not 
addressed. 
Orme 
2010 
(177) 
1. A network (“multiple-treatment”) meta-analysis using latanoprost as a reference, but with a limited number of direct comparisons for many treatments in the 
network. 2. ITT analysis and blinding by trial not addressed. 3. Classical meta-analysis not performed. 
  *Reported in a previous assessment (86); #                ; IOP = Intraocular Pressure; ITT = Intention-To-Treat. 
IIn STATA (metan), CMA and R (metafor), random-effects meta-analysis by trial size subgroups based on displayed data. Using displayed data on trial size (>100 or <100; or continuous), 
duration (<6 or >6 months; or continuous) and allocation concealment (yes/no), could not replicate the reported meta- regression results (SAS proc mixed; metareg in STATA; metafor in R).
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4.2.5. Relationship between different compounds 
Only the reviews achieving moderate level of quality of evidence (165, 167, 168, 175, 177) 
were considered for evaluation of relationship between treatments.  
 
4.2.5.1. Efficacy 
Based on IOP reduction after 3 months of treatment, Orme et al. (177) ranked 6 mono-
compound medications in the following order (most effective to least effective): bimatoprost, 
latanoprost, travoprost, CAI group, β-blockers group without timolol, timolol.  
However, many of the differences between treatments were very small and although 
statistically significant they do not appear practically relevant. Table 4 summarizes point-
estimates of pair-wise differences in IOP reduction reported by Orme et al. (177).  
Assuming that the limits of -1.0 to +1.0 mmHg for IOP reduction are reasonable limits of 
therapeutic equivalence (174), the three PGAs appear to be equivalent. In a series of pair-wise 
comparisons, Aptel et al. (168) calculated somewhat larger differences between bimatoprost 
and latanoprost, and between bimatoprost and travoprost but still, all were well within the -1.0 
to +1.0 range. Li et al (165) compared travoprost to bimatoprost and reported zero difference 
(point-estimate 0.08 mmHg), while the difference between travoprost and latanoprost was -
0.57 mmHg. Despite these variations, it appears reasonable to conclude that the IOP-reducing 
potential of the three PGAs is not relevantly different. 
According to Orme et al. (177), PGAs are more effective than other evaluated drugs, but in 
this respect they should be considered individually. Bimatoprost seems to be relevantly 
superior to CAI, β-blockers other than timolol, and timolol, whereas latanoprost and 
travoprost showed a relevant difference only in relation to timolol (Table 27).  
The findings of Li et al. (165) confirmed the size of the difference between travoprost and 
timolol, whereas Fung et al. (167) reported a relevant difference between latanoprost and 
brimonidine (point-estimate 1.10 mmHg).  
Finally, according to Orme et al. (177), CAI as a group, timolol and other β-blockers do not 
seem to relevantly differ regarding their IOP-reducing potential (Table 27). However, these 
relationships were estimated practically exclusively through indirect comparisons and we 
found no other evidence of at least moderate quality that would relate these treatments to each 
other. 
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Table 27. Point-estimates of differences (mmHg) between pairs of treatments in IOP 
reduction at 3 months vs. baseline as determined in a network meta-analysis by Orme et 
al (177). A positive value indicates a greater reduction by the “row drug” vs. a “column 
drug” and a negative value indicates the opposite. Bolded are values that exceed a 
difference of  1.0 mmHg and underlined are the differences close to this limit.*  
 Bimatoprost Latanoprost Travoprost CAI as a group BB w/o timolol Timolol 
Bimatoprost --- 0.45 0.47 0.97 1.09 1.41 
Latanoprost -0.45 --- 0.02 0.52 0.64 0.96 
Travoprost -0.49 -0.02 --- 0.50 0.62 0.94 
CAI as a group -0.97 -0.52 -0.50 --- 0.12 0.44 
BB w/o timolol -1.09 -0.64 -0.62 -0.12 --- 0.32 
Timolol -1.41 -0.96 -0.94 -0.44 -0.32 --- 
BB = β-Blockers; CAI = Carbonic Anhydrase Inhibitors; w/o = Without 
* We assumed that the limits of -1.0 to +1.0 mmHg for a difference in IOP reduction could be reasonably accepted as limits 
of equivalence (174). 
 
4.2.5.2. Tolerability/safety 
The only adverse event addressed by all 5 reviews was conjunctival hyperemia.  
The most comprehensive assessment was that by Orme et al. (177), i.e., through a network 
meta-analysis including 73 RCTs. Ranking of mono-compound drugs from the lowest to the 
highest incidence of conjunctival hyperemia was: timolol, dorzolamide, brimonidine, 
latanoprost, travoprost and bimatoprost. Betaxolol was also ranked, but based only on one 
trial arm with only 34 patients (177). Table 28 summarizes point-estimate odds ratios (ORs). 
Odds of hyperemia with latanoprost appear to be around 3-fold and around 5-fold lower than 
with travoprost and bimatoprost, respectively (Table 28). Similar estimates were reported by 
Hornubia et al. (175), whereas estimates provided by Aptel et al. (168) and Li et al. (165) 
where somewhat smaller (1.5-2.0-fold lower odds).  
While Orme et al. (177) indicated no relevant difference between travoprost and bimatoprost 
(Table 28), Aptel et al. (168) and Li et al. (165) reported a significantly lower incidence with 
travoprost – ORs around 0.86 (168) and around 0.65 (175), respectively.  
Overall, it seems reasonable to conclude that latanoprost conveys the lowest risk of 
conjunctival hyperemia among PGAs, whereas evidence on travoprost vs. bimatoprost is 
inconclusive. 
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The review by Orme et al. (177) is the only evidence of at least moderate quality about safety 
relationships between non-PGA compounds and indicates no relevant difference between 
timolol, brinzolamide and brimonidine in respect to conjunctival hyperemia (Table 28).  
It also demonstrates that, in this respect, bimatoprost is considerably worse than any of these 
drugs, whereas latanoprost and travoprost appear worse than timolol (Table 28).  
Data from Li et al. (165) and Fung et al. (167) confirm higher incidence with travoprost vs. 
timolol (OR 11.5) and no difference between latanoprost and brimonidine (relative risk 
around unity), respectively. 
Fung et al. (167) compared latanoprost to brimonidine in respect to a number of AEs besides 
hyperemia (e.g., eyelid disorders, visual disturbances, keratopathy, dry eye, hypertrichosis, 
fatigue, headache) indicating no difference between the two.  
Li et al. (165) indicated considerably higher odds of eye-lash changes and iris pigmentation 
with travoprost as compared to timolol or latanoprost.  
However, considering the specifics of the systematic reviews of Adverse Events (AEs) (87), 
in respect to these assessments quality of evidence provided by the two reviews is less than 
moderate:  
 none of the included primary trials was specifically designed to assess 
safety/tolerability;  
 neither review evaluated the quality of primary trials specifically in respect to AEs 
recording, evaluation and reporting;  
 data on most of the outcomes were available from only a few trials and prevalence of 
“zero event cells” was rather high. 
 
4.2.5.3. Combining efficacy and safety 
None of the five reviews (165, 167, 168, 175, 177) attempted to rank treatments based on a 
composite criterion combining efficacy and tolerability/safety.  
Data suggest that among PGAs latanoprost has the most favorable trade-off between efficacy 
and tolerability. However, none of the presented reviews included trials with preservative-free 
PGA formulations that have recently emerged (179-183), and this conclusion might change in 
the near future.  
The existing evidence does not point-out to any relevant difference regarding efficacy and 
safety of non-PGA compounds dorzolamide, brimonidine, timolol and “other” β-blockers.  
 69 
 
Compared to PGAs, and in addition to (at least somewhat) lower efficacy, they are limited by 
the fact of twice or thrice daily administration (vs once daily). It appears reasonable to 
consider them as alternative options when PGAs are contraindicated or not tolerated. 
 
Table 28. Differences between pairs of treatments in incidence of conjunctival 
hyperemia as determined in a network meta-analysis by Orme et al (177). Differences 
are expressed as odds ratios: values >1.0 indicate a greater incidence for the “row drug” 
vs. a “column drug”, and values <1.0 indicate the opposite. 
 Timolol Dorzolamide Brimonidine Latanoprost Travoprost Bimatoprost 
Timolol --- 1* 1* 0.56 0.18 0.11 
Dorzolamide 1* --- 1* 1* 1* 0.22 
Brimonidine 1* 1* --- 1* 1* 0.21 
Latanoprost 1.78 1* 1* --- 0.32 0.21 
Travoprost 5.55 1* 1* 3.12 --- 1* 
Bimatoprost 9.09 4.54 4.76 4.76 1* --- 
*Odds ratios around 1 (1) indicate a lack of a statistically significant difference (95% confidence intervals around the odds 
ratio extend from below to above unity).
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5. DISCUSSION 
Glaucoma in general is a complex and multifaceted condition. Since it is the leading cause of 
irreversible blindness worldwide, its epidemiology, etiology and treatment have been 
extensively investigated.  
The present work addressed only one component of this group of optical neuropathies, but the 
one that bears the major part of the healthcare burden – primary open angle glaucoma 
(POAG) and ocular hypertension (OHT). Within this still broad field, the focus was on three 
specific questions:  
 What is the existing evidence on factors other than the increased IOP that are 
potentially modifiable or could be used for timely identification of people at an 
increased risk of POAG? 
 What is the existing evidence on relative efficacy and safety of mono-compound 
topical IOP-lowering medications in treatment of POAG/OHT?  
 What is the existing evidence on relative cost-effectiveness of the mono-
compound topical IOP-lowering medications in treatment of POAG/OHT? 
These questions are relevant for practical reasons: 
 a) although treatment of increased IOP has been clearly shown to preclude progression of 
OHT to POAG, it is of interest to introduce, if possible, other measures that would either be 
supportive to the treatment of IOP or would reduce occurrence of IOP (and thus preclude the 
need for treatment). Likewise, it is of interest to timely identify subjects with an increased risk 
of POAG;  
b) mono-compound topical treatments are the preferred initial IOP-reducing treatment and 
identification of those with the best trade-off between efficacy and safety would help optimize 
the treatment. Whereas identification of drugs with the best cost-effectiveness profile would 
be particularly useful for developing countries with restricted public health resources. 
In line with the methodology implemented in the attempts to resolve the posed questions, the 
results are discussed in the format that is standard for overview of reviews. 
 
 71 
 
5.1. Risk factors for POAG 
5.1.1. Overall completeness and applicability of evidence 
Age, gender and ethnicity have long been recognized as factors associated with POAG, but 
the quest for factors other than IOP influencing POAG (or IOP) occurrence has been 
particularly focused on potentially modifiable factors.  
The present systematic review of reviews identified a number of narrative reviews dealing 
with a number of lifestyle, environmental and co-morbidity factors that were considered in 
relation to POAG occurrence. However, the number and quality of the individual primary 
studies were limited not allowing sound conclusions.  
On the other hand, genetic risk factors were evaluated in a large number of systematic reviews 
and meta-analyses. However, most of them included small candidate-gene association studies 
providing a very low level of quality of evidence and were not further evaluated in the present 
work.  
We included 3 meta-analyses of data from genome-wide association studies (GWAS) and 2 
narrative reviews that intended to summarize and synthesize the complete knowledge on the 
genetic background of POAG to emphasize that the genetic background of POAG is not 
addressed only through simple associations, but remains extremely complex.  
 
5.1.2. Quality of evidence 
Our research question was very complex as it pertained to different risk factors for POAG 
development: those potentially modifiable for preventive purposes and those that could serve 
as “markers” of high risk of POAG, although not necessarily modifiable. 
Considering lifestyle factors (which are potentially modifiable) and co-morbidity factors 
(which, if present, could “signal” a potentially increased risk of glaucoma) different levels of 
quality of evidence were established:  
 evidence of relationship between POAG and myopia ( myopia can be treated, but 
treatment of myopia has no effect on the posterior segment and on the “link” 
between myopia and POAG) and circulating levels of homocysteine, folic acid, 
vitamin B12 and vitamin B6 (potentially modifiable by diet) – low quality of 
evidence; inconclusive;  
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 evidence of relationship between cigarette smoking (modifiable lifestyle) and 
POAG and between diabetes mellitus (DM) and POAG (potentially modifiable by 
treatment) – low quality of evidence from the existing systematic reviews/meta-
analyses of primary studies. However, we identified several large cohort studies that 
provided high quality evidence about the relationship between DM, cigarette 
smoking and POAG. 
Systematic reviews/meta-analyses addressing non-modifiable but “identifying” risk factors 
for POAG were exclusively genetic studies. The vast majority of these systematic reviews 
were of low quality and inconclusive. However, 3 pooled analyses of large GWAS studies 
provided high quality of evidence of a causative role of certain genes in POAG. 
 
5.1.3. Potential biases in the overview process 
We avoided any conclusions where the overall body of evidence was not at least of moderate 
quality. In this way, we avoided potential biases that could have been introduced by low-
quality primary studies or systematic reviews.  
Regarding potentially modifiable risk factors, high quality of evidence was available 
regarding smoking and DM as risk factors for POAG. However, this high quality evidence 
was not derived from the existing systematic reviews but from primary studies that we 
identified and meta-analysis that we performed. Protection from bias in this case was 
achieved by a thorough literature search and implementation of multivariate meta-analysis. 
Regarding genetic factors in POAG; three pooled analyses of large GWAS studies provided 
high quality of evidence since all individual studies as well as the data pooling methodology 
were appropriate. 
At the overview level, we could have introduced bias by omission of one systematic review 
that was written in Chinese. 
 
5.1.4. Agreements and disagreements with other studies or reviews 
To the best of our knowledge, this is the only overview of systematic reviews dealing with 
risk factors for POAG. 
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5.1.5. Conclusions 
5.1.5.1. Implications for practice 
Over the years, different studies proposed several modifiable and non-modifiable risk factors 
besides IOP to play a role in the POAG development. The present overview indicates that 
despite a large number of studies, elevated IOP still remains the major risk factor.  
The observed association between DM and occurrence of POAG in women most likely has no 
practical relevance – the association was weak, indicating only a minor (if any) contribution 
of DM to POAG. Vice-versa, POAG is of only a minor relevance in the broad spectrum of 
consequences of DM. 
The evidence about genetic factors in the development of POAG, at the moment, appears also 
to be of minor practical relevance – according to the existing data, individual genes provide 
only minor contributions to the risk of POAG and do not seem to be interesting as “markers” 
to be used in early detection of “subjects at a particular risk”. However, these associations are 
particularly relevant in understanding the pathophysiology of POAG and potential 
development of future therapies. 
 
5.1.5.2. Implications for research 
A large number of potentially modifiable risk factors for POAG have been addressed over the 
years: lifestyle (e.g., smoking, alcohol consumption, physical activity, diet/nutrition) and co-
morbidity (e.g., DM, hypertension, myopia), but most of them (apart from DM and smoking) 
apparently only superficially.  
The existing data do not provide any relevant “signals” that relevant discoveries in this area 
should be expected. However, it should be kept in mind that low quality of evidence is no 
sound basis for either confirmative or negative conclusions. On the other hand, considerable 
developments have been made in the field of understanding the genetic basis of glaucoma – 
primarily in identification of genes and genetically determined “defects” in functioning of 
molecules involved in the development of glaucoma.  
On one hand, these discoveries might, provide the basis for development of future therapies. 
On the other hand, they might set the grounds for evaluation of a potential interplay between 
genetically determined factors and modifiable factors.
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5.2. Mono-compound IOP-lowering drugs in POAG/OHT 
5.2.1. Overall completeness and applicability of evidence 
The present work addressed only a segment of pharmacological treatment of glaucoma, i.e., 
only POAG/OHT and only mono-compound drugs, and aimed to address evidence of their 
relative efficacy, tolerability and cost-effectiveness profile specifically through evaluation of 
systematic review/meta-analysis and not individual trials.  
The choice of the method resulted in the fact that all currently most commonly used mono-
compound drugs were embraced by the present evaluation, but some older individual drugs or 
drug classes (e.g., α-agonists, β-blockers or CAI; cholinomimetics) and newer products like 
preservative-free formulations, were not - simply due to the fact that so far they have not been 
subject to systematic reviews. Cost-effectiveness profile of these drugs was not evaluated as 
no study related to this topic was found. However, these facts do not pose any major 
limitation to the present work.  
Over the years, the evaluated drugs have positioned themselves as preferable to most of the 
older ones and have become standards. In respect to new developments, they could be 
considered as “of progressively declining interest”. However, assessment of their relative 
efficacy and safety is of practical relevance for at least two reasons: 
a) full evaluation of newer or emerging treatments will take some time; 
b) new products, regardless of whether conveying conceptually new treatment options or 
“just” potential improvements to known strategies, are inevitably more expensive 
particularly considering the fact that “standards” are already available in generic versions.  
While new options might eventually prove to be highly cost-effective, optimization of the use 
of pharmacological armamentarium at hand seems a reasonable effort.  
 
5.2.2. Quality of evidence 
Our research question was relatively complex as it pertained to a number of individual mono-
compound drugs and also to both efficacy and safety.  
None of the assessed reviews provided high quality evidence and five were considered to 
provide evidence of moderate quality. However, this judgment does not apply uniformly to all 
of the addressed topics.   
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A moderate quality body of evidence is available for:  
a) assessment of relationships between PGAs latanoprost, bimatoprost and travoprost in 
respect to efficacy and incidence of conjunctival hyperemia; 
b) assessment of relationships between the three PGAs and non-PGA compounds timolol, 
other β-blockers, brimonidine and CAI (dorzolamide, or combined data for dorzolamide 
and brinzolamide) in respect to efficacy and conjunctival hyperemia.     
Evidence about relationships between non-PGA compounds regarding efficacy and evidence 
regarding any other safety/tolerability aspect apart from conjunctival hyperemia is of less than 
moderate quality. 
 
5.2.3. Potential biases in the overview process 
All conclusions on mutual treatment comparisons in the present overview are based on 
evidence of moderate quality. Where this level of quality was not available, no conclusions 
were drawn. In this way, the conclusions are fairly protected from biases that could have been 
introduced by the primary trials or systematic review methodological flaws.  
At the overview level, we could have introduced bias by omission of one systematic review 
that was written in Chinese. Another source of bias could be the fact that we did not include 
individual studies, i.e., not even those published since the last systematic review on the topic.  
 
5.2.4. Agreements and disagreements with other studies or reviews 
To the best of our knowledge, this is the only overview of systematic reviews dealing with 
efficacy and safety of mono-compound IOP-lowering drugs in POAG/OHT. 
 
5.2.5. Conclusions 
5.2.5.1. Implications for practice 
Over the years, PGAs have emerged as preferred mono-compound treatments in POAG/OHT. 
The present overview indicates that among PGAs, latanoprost has the most favorable trade-
off between efficacy and tolerability.  
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Use of travoprost or bimatoprost as a first-line treatment of POAG/OHT is not very likely to 
result in a relevantly better efficacy, but is highly likely to result in conjunctival hyperaemia, 
a common cause of patient-driven discontinuation of treatment. 
Non-PGA treatments should be considered as alternatives when PGAs are contraindicated or 
not tolerated. While traditionally β-blockers, particularly timolol, have been considered as the 
major non-PGA treatment option, there is no clear-cut evidence that supports preference of 
timolol over CAI or brimonidine either regarding efficacy or regarding safety. 
 
5.2.5.2. Implications for research 
The medications addressed in the present overview represent the current standard choice of 
mono-compound IOP-lowering drugs and are likely to remain relevant for at least some time 
in the future. Still, certain questions about their relative efficacy and tolerability cannot be 
answered with certainty since the body of available evidence does not meet the criteria of at 
least moderate quality. Furthermore, we could not find any systematic review/meta-analysis 
that evaluated cost-effectiveness profile of these drugs. 
With the on-going pharmacological developments in the field, these drugs are not very likely 
to be engaged in major primary trials in the future. However, the number of the existing 
primary trials – those addressed in the overviewed systematic reviews and those published 
over the last few years (or still on-going) is considerable, and many of those are actually high-
quality individual trials. Under such circumstances, new developments in the field of research 
synthesis seem a convenient and powerful tool for converting the existing primary data into 
evidence of relevant quality.  
Many of the reviews assessed in the present work suffered for serious methodological 
limitations, but they could all be avoided. It appears likely that adequate quality of evidence 
could be generated with improved assessment of quality of the primary trials, inclusion of 
only high-quality primary data, appropriate assessment of data combinability, sensitivity 
analyses and appropriate implementation of “standard” and novel (network) data-pooling 
techniques. 
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6. OVERALL CONCLUSIONS 
Despite a number of individual studies and systematic reviews in the field of POAG and 
continuous research interest in this topic, many questions still remain unanswered. 
Relationship between individual risk factors and development of POAG is difficult to prove 
as POAG most likely results from complex interactions between genetic and demographic, 
lifestyle, environmental and co-morbidity factors. Based on the available evidence evaluated 
in this overview we conclude that: 
1. Several lifestyle factors (which are potentially modifiable) and co-morbidity factors 
(which, if present, could “signal” a potentially increased risk of glaucoma) apart from IOP 
were identified (smoking, DM, coffee or alcohol drinking, hormone replacement therapy, 
physical activity, diet, etc.). 
2. Available evidence on most of the addressed potentially modifiable POAG risk factors in 
general derives from low quality reviews and primary trials, therefore data do not provide the 
basis for sound conclusions.  
3. A few high quality individual cohort studies confirm that there is no association between 
smoking and the risk of POAG, whereas DM weakly increases the risk of POAG in women.  
4. Available evidence on associations between occurrence of POAG and presence of certain 
genetic markers derives from very low quality reviews and primary trials, therefore were not 
further evaluated in the present work. Only 3 pooled analyses from large GWAS studies 
provide high quality evidence of involvement of several genetic “defects” in pathophysiology 
of POAG.  
5. Observational studies with low risk of bias are needed to assess the relationship between 
POAG and risk factors. Long-term follow-up cohort studies, adjusted for confounders should 
be designed to assess non-genetic risk factors, whereas GWAS are needed for genetic ones.  
6. Available evidence of at least moderate quality on efficacy and safety of mono-compound 
topical IOP-lowering medications in treatment of POAG/OHT was identified. 
7. The existing evidence indicates that among prostaglandin analogues (PGAs), latanoprost 
has the most favourable trade-off between efficacy and tolerability.  
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8. Use of travoprost or bimatoprost as a first-line treatment is not very likely to result in a 
relevantly better efficacy, but is highly likely to result in conjunctival hyperaemia, a common 
cause of patient-driven discontinuation of treatment. 
9. Non-PGA treatments should be considered as alternatives when PGAs are contraindicated 
or not tolerated. There is no clear-cut evidence that supports preference of timolol over 
carbonic anhydrase inhibitors or brimonidine either regarding efficacy or regarding safety. 
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7. SUMMARY 
AIM: A systematic synthesis of the existing research evidence in the field of POAG is an 
appropriate methodological approach to achieve the aim of improved overall management of 
the disease. In the present study we focused on evidence on risk factors other than intraocular 
pressure (IOP) that are potentially modifiable and/or could be used for timely identification of 
people at high risk of POAG; and on relative efficacy, tolerability and cost-effectiveness 
profile of mono-compound topical IOP-lowering medications in treatment of POAG/OHT. 
METHODS: Systematic review of systematic reviews/meta-analysis of primary prognostic 
studies and randomized controlled trials (RCTs). A thorough and sensitive search of Medline, 
Scopus and Cochrane Databases was performed. Methodological quality of reviews and 
quality of evidence were assessed using the AMSTAR checklist and the GRADE system, 
respectively. Comprehensive Meta-Analysis softaware version 2.2.064 2011 ( Biostat Inc., 
Englewood, NJ, USA) and SAS for Windows 9.2 (SAS Institute Inc., Cary, NC, USA) 
(macros for multiple modifier meta-regression) were used for data analyses. Conclusions were 
based on the evaluation of the best available evidence. 
RESULTS: 3606 records were identified through two different search strategies; 25 studies 
met the inclusion criteria for evaluation of POAG risk factors and 16 for the evaluation of 
efficacy and safety of mono-compound topical IOP-lowering drugs. Only six reviews 
achieved an overall "moderate” quality of evidence. Reviews dealing with risk factors were of 
low quality in general, whereas individual studies indicated that there were no association 
between smoking and POAG and a weakly increased risk of POAG in diabetic women. 
“Moderate quality” reviews dealing with therapy indicate that prostaglandin analogues 
(PGAs) should be considered equivalent regarding efficacy, but latanoprost is relevantly 
better tolerated than bimatoprost or latanoprost. Non-PGA compounds do not relevantly differ 
between each other in either efficacy or safety. Timolol and brimonidine are relevantly less 
effective than all PGAs. The same is true for CAI vs. bimatoprost. Regarding tolerability, 
timolol is superior to all PGAs and brimonidine and CAI are superior to bimatoprost. 
Conclusion: Several potential risk factors for POAG apart from IOP were identified, 
however, no conclusion regarding their contribution could be drawn as the available 
information derives from low quality evidence. Available evidence of mono-compound IOP-
lowering medications in treatment of POAG/OHT was identified. Moderate quality evidence 
indicates latanoprost as a mono-compound topical treatment with a most favourable trade-off 
between benefits and harms. 
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8. SAŽETAK 
CILJ: U svrhu poboljšanja cjelokupnog upravljanja bolešću, poduzeta je sustavna sinteza 
postojećih znanja u području primarnog glaukoma otvorenog kuta (POAG). U ovom smo se 
istraživanju usredotočili na dokaze o postojanju čimbenika rizika za POAG, mimo povišenog 
intraokularnog tlaka (IOP), koji su potencijalno promjenjivi i/ili bi se mogli koristiti za 
pravovremenu identifikaciju ljudi s visokim rizikom za POAG; i na relativnu djelotvornost, 
podnošljivost i isplativost monokomponentnih topikalnih lijekova za snižavanje IOP u 
liječenju POAG, odnosno, okularne hipertenzije (OHT).  
METODE: Pregled sustavnih pregleda/meta-analiza primarnih prognostičkih studija i 
randomiziranih kontroliranih pokusa (RCT). Poduzeto je temeljito i osjetljivo pretraživanje 
Medline, Scopus i Cochrane baze podataka. Metodološka kvaliteta ocijenjena  pomoću 
AMSTAR ljestvice a ukupna kvaliteta dokaza uporabom GRADE sustava. Za analizu podatka  
korišteni su ComprehensiveMetaAnalysis softaware verzija 2.2.064 2011. (Biostat Inc., New 
Jersey, USA) i SAS za Windows 9.2 (SAS Inc., Cary, NJ, USA) (makro za multiplu meta-
regresiju). Zaključci se temelje na najboljim dostupnim dokazima. 
REZULTATI: Identificirano je 3606 zapisa uporabom dvije različite strategije pretraživanja; 
25 studija zadovoljilo je kriterije za uključivanje u procjenu čimbenika rizika za POAG, a 16 
studije za uključivanje u procjenu djelotvornosti i sigurnosti monokomponentnih topikalnih 
lijekova za snižavanje IOP u bolesnika s POAG/OHT. Samo šest sustavnih pregleda postiglo 
je "srednju" razinu kvalitete dokaza. Studije čimbenika rizika bile su, sveukupno, niske 
kvalitete, a pojedinačne studije pokazale su da nema povezanosti između pušenja i POAG, te 
da je u žena s dijabetesom blago povećan rizik za nastanak POAG. Dokazi " srednje kvalitete" 
pokazuju da prostaglandinske analoge (PGA) treba smatrati ekvivalentnima u pogledu 
djelovornosti, te da je latanoprost znatno bolje podnošljiv od travoprosta i bimatoprosta.. 
Ostali, „ne-PGA“, lijekovi, ne razlikuju se bitno jedni od drugih u pogledu djelotvornosti i 
sigurnosti. Timolol i brimonidin relevantno su manje djelotvorni od svih PGA. Isto vrijedi i za 
inhibitore karboanhidraze (CAI) u usporedbi s bimatoprostom. U pogledu podnošljivosti, 
timolol je superioran u odnosu na sve PGA i brimonidin, a CAI su superiorni bimatoprostu.  
ZAKLJUČAK: Identificirano je nekoliko potencijalnih čimbenika rizika za POAG osim 
IOP, međutim, s obzirom na nisku razinu dokaza, nisu mogući racionalni zaključci o 
doprinosu pojedinih čimbenika riziku za nastanak POAG. Dokazi srednje kvalitete pokazuju 
da kao monokomponentni topikalni tretman, latanoprost ima najbolji odnos djelotvornosti i 
sigurnosti. 
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